

FINAL PROGRAM

Ho Chi Minh City, Vietnam
12 – 15 November 2017



XXII

World Congress on Parkinson's
Disease and Related Disorders

Scientific Host



Congress Organizer



Local Partner



www.iaprd-world-congress.com

TABLE OF CONTENTS

Welcome Words	3
---------------------	---

SCIENTIFIC PROGRAM

Floor Plan	6
Session Descriptions and Types	7
Sunday, 12 November 2017	
Program Overview	10
Scientific Program	12
Monday, 13 November 2017	
Program Overview	16
Scientific Program	18
Tuesday, 14 November 2017	
Program Overview	28
Scientific Program	30
Wednesday, 15 November 2017	
Program Overview	44
Scientific Program	46
Poster Exhibition	50
Information for Speakers	76
Information for Abstract Authors	77
Index of Authors and Speakers	78
Abstract E-Book	86
IAPRD Congress Awards	87

GENERAL CONGRESS INFORMATION

Registration	90
Certification	91
Travel Grants	92
Social Program	93
Ho Chi Minh City	95
Congress Venue – GEM Center	96
Good to know	98

IAPRD ASSOCIATION

About the IAPRD	102
Associate Member Sign Up Form	103
IAPRD Committees	104

INDUSTRY

Exhibition Floor Plan	108
Exhibitors	109
Sponsors / Supporters	110
Corporate Sessions	112
Data Protection	114
Imprint	115

WELCOME

Ho Chi Minh City, Vietnam 12-15 November 2017

On behalf of the Board of the International Association of Parkinsonism and Related Disorders, it is our pleasure to welcome you to the XXII World Congress on Parkinson Disease and Related Disorders!

The theme of this Congress is “Two Centuries of Movement Disorders: Transformation of Clinical Care”. Many of our sessions are designed to reflect this theme, tracing a timeline from historical insights to current state of the art therapy and promising future breakthroughs. We have assembled a truly international faculty to provide a breadth of viewpoints and experience, and facilitate the global sharing of therapeutic strategies that can enhance the quality of life of patients worldwide. The Congress is designed to promote interactions among those with different perspectives, from basic scientists to devoted clinicians, and from junior colleagues to seasoned experts. Educational and practical hands-on opportunities feature prominently, as do debates on some of the most important and controversial topics in movement disorders.

While you are here, we hope you will explore Vietnam’s diverse landscape, including the hills and densely-forested mountains, the Mekong delta, and a 2,140-mile-long coastline. Ho Chi Minh City, more popularly known as Saigon, was once called the Pearl of South East Asia and is now Vietnam’s largest city and tourist destination in its own right.

We look forward to an educational and interactive Congress in this beautiful and exotic venue!



Daniel Truong, MD, Prof hc
*Congress Chair
President of IAPRD*



Hubert H. Fernandez, MD
*Chair
Scientific Program Executive
Committee*




Elena Moro, MD, PhD
*Chair
Scientific Program
Committee*




SCIENTIFIC PROGRAM


FLOOR PLAN



CASTOR
Level 5



MEDIA CHECK
Level 4



POLLUX
Level 3

SESSION DESCRIPTIONS AND TYPES

PLENARY SESSIONS

These sessions are designed to highlight the most relevant discoveries covering the main topics of the Congress, delivered by the most respected and leading clinical experts, basic scientists and other health care professionals. Due to the high importance of these sessions, there will be no other ongoing sessions during a plenary.

“PHO” HOT TOPIC SESSIONS

These sessions are designed to serve as a platform for the most ground-breaking, intriguing, and talked about issues in movement disorders. After the lectures the typical Vietnamese “Pho” Soup will be served in the conference room.

POINT-COUNTERPOINT INTERACTIVE SESSIONS

These sessions offer lively and hopefully fruitful discussions on controversial issues in a debate format. Each speaker will have 30 minutes to discuss their view point, followed by 15 minutes of Q and A between the debaters, and 15 minutes of Q and A from the audience.

“GLOBAL” VIDEO SESSIONS

These predominantly video-based, practical sessions aim to illustrate the different phenomenologies of movement disorders from around the globe, including differential diagnoses and final diagnosis.

“TIMELINE” PARALLEL SESSIONS

In keeping with our theme of “Two Centuries of Movement Disorders”, talks for each session follow the “Past, Present, Future” format. Examples of “past” topics include historical overview, clinical presentation and pathophysiology of the disease; “present” topics include and current diagnostic approach and treatment options; and “future” topics include the latest research and developments on the topic.

SKILLS WORKSHOP

These sessions are intended to be interactive and focus on procedures related to the treatment of various movement disorders, including botulinum toxin injections and deep brain stimulation.

CLINICAL PRACTICE SESSIONS

Back by popular demand. These sessions will cover all aspects of Parkinson's disease and other movement disorders, and follow the format of "IAPRD Textbook of Parkinson Disease and Other Movement Disorders" to serve the educational mission of the IAPRD. These sections are generally clinically based and practical in nature, discussing key disease features, diagnosis, work-up and treatment.

All presentations of the Clinical Practice Sessions will be videotaped.

Following the Congress, videos of the Clinical Practice sessions will be available on IAPRD's new educational platform, currently being developed in conjunction with [evidentia.med](#). The online platform will be free of charge and available to registered neuroscientists and medical health professionals worldwide.

CORPORATE SESSIONS (over lunch)

These sessions, sponsored by industry, will be held during the lunch break (from 12:00 to 13:30 PM daily).

These sessions are supported, in part, by funding from industry.

All support will be managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support.

MEET THE PROFESSOR

"Meet the Professor" is a great opportunity to interact with some of the most respected and accomplished movement disorder experts in the world.

ORAL POSTER SESSIONS

Authors are required to attach their posters to the appropriate poster boards. Posters will be displayed at the poster area within the Exhibition.


Authors for Oral Poster Presentations are expected to be present at their poster boards during the Oral Poster Session.



PROGRAM OVERVIEW

SUNDAY
12 November 2017

Room	Plenary	Room „Pollux 1“	Room „Pollux 2“	Room „Castor 1“
09:30				
10:00				Pre-Congress Corporate Session
10:30				
11:00				
11:30				
12:00				
12:30				
13:00	Coffee Break			
13:30		Introduction to Parkinson Disease	From Mice to Primates: New Animal Models of Movement Disorders	Focusing on Genetics and Imaging in Movement Disorders
14:00				
14:30				
15:00	Coffee Break			
15:30	Can Biomarkers Lead Us to Understanding and Conquering Parkinson Disease?			
16:00				
16:30				
17:00	Coffee Break			
17:30	Opening Ceremony & Melvin Yahr Lectures			
18:00				
18:30				
19:00				
19:30				
20:00				

 Plenary Sessions

 Timeline Parallel Session

 Point-Counterpoint Interactive Session

 Clinical Practice Session


Sunday, 12 November 2017

SUNDAY
12 November 2017


Room „Castor 2“	Poster Exhibition	Meet the Professor Lounge (Exhibition)
--------------------	-------------------	---

Dementia With Lewy Bodies and Parkinson Disease Dementia: Is It the Same Disease?	Oral Poster Session 1	Meet the Professor 1 Joachim K. Krauss
--	-----------------------	---

 Pho Hot Topic Session

 Corporate Session

 Skills Workshop

 Meet the Professor

 Oral Poster Session

 Global Video Session

SCIENTIFIC PROGRAM

SUNDAY
12 November 2017

10:00 – 13:00	Pre-Congress Corporate Session (see page 112)	Room Castor 1
13:30 – 15:00	Meet the Professor 1 <i>Professor: J. Krauss, Hannover, Germany</i>	Meet the Professor Lounge (Exhibition)
13:30 – 15:00	Focusing on Genetics and Imaging in Movement Disorders <i>Chair: S. Fujioka, Fukuoka, Japan A. Puschmann, Lund, Sweden</i>	Room Castor 1
	Learning Objectives	
	<ul style="list-style-type: none"> To explain the status of gene based therapies for movement disorders To describe genetic testing in movement disorders To discuss the current status of imaging techniques in understanding movement disorder pathology 	
13:30 – 14:00	The Promise of Gene Based Technology in Movement Disorders <i>N. Hattori, Tokyo, Japan</i>	
14:00 – 14:30	The Most Relevant Advances in Genetic Testing in Movement Disorders <i>H.-F. Shang, Chengdu, Sichuan, China</i>	
14:30 – 15:00	Imaging Techniques That are Leading the Way in Understanding Movement Disorders <i>J. Stoessl, Vancouver, Canada</i>	
13:30 – 15:00	Dementia with Lewy Bodies and Parkinson Disease Dementia: Is It the Same Disease? <i>Chair: C. Colosimo, Terni, Italy</i>	Room Castor 2
	Learning Objectives	
	<ul style="list-style-type: none"> To outline the evidence for and against considering dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) as the same disease 	
13:30 – 14:00	Dementia with Lewy Bodies and Parkinson Disease Dementia: It is the Same Disease! <i>J. Friedman, Rhode Island, United States</i>	
14:00 – 14:30	Dementia with Lewy Bodies and Parkinson Disease Dementia: It is NOT the Same Disease! <i>F. Valldorriola, Barcelona, Spain</i>	
14:30 – 14:45	Debate	
14:45 – 15:00	Question and Answer	

OP-1
13:30 – 15:00

Oral Poster Session 1
Basic Neuroscience & Other Movement Disorders
(4 minutes oral presentation followed by 2 minutes Q&A)

**Poster
Exhibition**

*Chair: A. Espay, Cincinnati, United States
L. Kalia, Toronto, Canada*


- OP-1-01 Botulinum toxin: central or peripheral mechanism of action?
Z. Lackovic, Zagreb, Croatia
- OP-1-02 Reprogramming in inflammatory response to neuronal damage induced by the brain LPS preconditioning: possible implications in a rat model of Parkinson's disease
M. Golpich, Kuala Lumpur, Malaysia
- OP-1-04 Clinico-genetic correlation in Indian spinocerebellar ataxia type 1 (SCA1) patients
A. Takkar, Delhi, India
- OP-1-05 Prevalence of hemochromatosis (HFE) gene mutations in Friedreich's ataxia patients and peripheral neuropathy
I. Singh, New Delhi, India
- OP-1-06 Movement disorders in patients with Japanese encephalitis: Experience in a tertiary care hospital in north eastern region of India
A. R. Barua, Guwahati, India
- OP-1-07 Voxel-based meta-analysis of gray and white matter volume reductions in spinocerebellar ataxia type 2
Q. Han, Chengdu, China
- OP-1-08 Non-motor symptoms in patients with autosomal dominant spinocerebellar ataxia
N. Kamble, Bangalore, India
- OP-1-09 Identification of microRNAs and their target genes modulating spinocerebellar ataxia type-2 (SCA2) pathogenesis
V. Swarup, New Delhi, India
- OP-1-10 Prevalence of Parkinson's disease and drug-induced parkinsonism from National Health Insurance Service Claims Data (NHISCD)
H.-I. Ma, Anyang, Republic of Korea
- OP-1-11 Clinical profile of normal pressure hydrocephalous patients with suggested phenotypic variants
M. K. Acharya, Kolkata, India
- OP-1-12 Phenotypic differences in genetically characterized spinocerebellar ataxia Type 2 (SCA2): a largest case series from India
A. K. Sonakar, New Dehli, India

SCIENTIFIC PROGRAM

SUNDAY
12 November 2017

OP-1-13 Clinical features and differential diagnostic criteria of PANDAS syndrome and Sydenham's chorea
I. Nasirova, Tashkent, Uzbekistan

OP-1-14 To study the genotype - phenotype correlation of Friedreich's ataxia (FRDA) patients in Indian population
I. Ahmad, Delhi, India

13:30 – 15:00  **From Mice to Primates: New Animal Models of Movement Disorders** **Room Pollux 2**

Chair: A. Pisani, Rome, Italy


Learning Objectives

- To describe the major animal models in Parkinson disease
- To describe the emerging animal models in progressive supranuclear palsy
- To describe the advances in animal models of dystonia

13:30 – 14:00 The Most Promising Models in Parkinson's Disease
A. Pisani, Rome, Italy

14:00 – 14:30 Emerging Models in Progressive Supranuclear Palsy
E. Hirsch, Paris, France

14:30 – 15:00 Progress in Dystonia Animal Models in the Last Decade
M. LeDoux, Memphis, United States

13:30 – 15:00  **Introduction to Parkinson Disease** **Room Pollux 1**

Chair: C. Singer, Miami, United States

Learning Objectives

- To outline the clinical definition of Parkinson disease
- To describe the signs of Parkinson disease that precede motor manifestations
- To describe the time course of motor signs in Parkinson disease

13:30 – 14:00 The Clinical Definition of Parkinson Disease
E. Ch. Wolters, Amsterdam, The Netherlands

14:00 – 14:30 Pre-Motor Manifestations in Parkinson Disease
C. Tanner, San Francisco, United States

14:30 – 15:00 Early and Late Motor Manifestations of Parkinson Disease
T. Simuni, Chicago, United States

In collaboration with evidentia.med

15:30 – 17:00 **Can Biomarkers Lead Us to Understanding and Conquering Parkinson Disease?** **Plenary**

*Chair: E. Ch. Wolters, Amsterdam, The Netherlands
D. Truong, Fountain Valley, United States*

Learning Objectives

- To describe the general features of biomarkers in Parkinson disease
- To understand the use of biomarkers to aid in early diagnosis of Parkinson disease
- To review the status of biomarkers in cognition and behavior in Parkinson disease

15:30 – 16:00 Unlocking the Mystery of Biomarkers: A Brief Introduction, its Challenges and Opportunities in Parkinson Disease
A. Chen-Plotkin, Philadelphia, United States

16:00 – 16:30 How Biomarkers Are Uncovering the Rate of Parkinson Disease Progression
J. Yarden, Haifa, Israel

16:30 – 17:00 The Emerging Role of Biomarkers in Cognition and Behavior in Parkinson Disease
L. Kalia, Toronto, Canada

17:30 – 19:30 **Opening Ceremony & Melvin Yahr Lectures** **Plenary**

17:30 – 17:35 Cultural Performance

17:35 – 17:45 Welcome
D. Truong, Fountain Valley, United States

17:45 – 18:15 Melvin Yahr Lecture I: The 200 Year Journey of Parkinson Disease: Reflecting on the Past and Looking Towards the Future
S. Fahn, New York, United States

18:15 – 18:45 Melvin Yahr Lecture II: Deep Brain Stimulation Surgery in Movement Disorders: Lessons From The Last 3 Decades
E. Moro, Grenoble, France; J. Krauss, Hannover, Germany

18:45 – 19:00 Cultural Performance

19:00 – 19:10 Burda Award Ceremony
T. Brücke, Vienna, Austria

19:10 – 19:20 Presentation of the Melvin Yahr Travel Award Winners 2017
*E. Ch. Wolters, Amsterdam, The Netherlands
D. Truong, Fountain Valley, United States*

19:20 – 19:25 Closing
D. Truong, Fountain Valley, United States

19:25 – 19:30 Cultural Performance

PROGRAM OVERVIEW

MONDAY
13 November 2017

Room	Plenary	Room „Pollux 1“	Room „Pollux 2“	Room „Castor 1“
08:00				
08:30				
09:00		Autonomic Dysfunction in Parkinson Disease	Neuropathology and Behavioral Dysfunction in Parkinson Disease	Focusing on New Targets for Therapy
09:30				
10:00	Coffee Break			
10:30	Understanding the Complex Web of Cognitive Dysfunction and Movement Disorders			
11:00				
11:30				
12:00	Lunch Break			Corporate Session 2
12:30				
13:00				
13:30	The Treatment of Parkinson Disease: 200 Years Later			
14:00				
14:30				
15:00	Coffee Break			
15:30				
16:00		Skills Workshop 1: Deep Brain Stimulation Surgery	Therapy for Parkinson Disease Part I	Focusing on Gut Microbiota
16:30				
17:00				
17:15				
18:00	IAPRD Annual General Meeting			
18:45				
19:00				

Plenary Sessions

Timeline Parallel Session

Point-Counterpoint Interactive Session

Clinical Practice Session

Monday, 13 November 2017

MONDAY
13 November 2017


Room „Castor 2“	Room „Castor 3“	Poster Exhibition	Meet the Professor Lounge (Exhibition)
-----------------	-----------------	-------------------	--

Is Parkinson Disease a Prion Disease?	Treating the Most Challenging Behavioral and Cognitive Issues in Parkinson Disease	Oral Poster Session 2	
---------------------------------------	--	-----------------------	--


Lunch Break

Are SPECT Scans Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders?	Are We Ready for Digital Technology in the Assessment and Management of Parkinson Disease?	Oral Poster Session 3	Meet the Professor 2 Stanley Fahn
---	--	-----------------------	-----------------------------------

 Pho Hot Topic Session

 Corporate Session

 Skills Workshop


 Meet the Professor

 Oral Poster Session

 Global Video Session

SCIENTIFIC PROGRAM

MONDAY
13 November 2017

- OP-2** **Oral Poster Session 2** **Poster Exhibition**
08:30 – 10:00 **Parkinson 1: Etiology/ Epidemiology/ Pathophysiology**
 *(4 minutes oral presentation followed by 2 minutes Q&A)*
- Chair: A. Pisani, Rome, Italy
E. Cereda, Pavia, Italy*
- OP-2-01** The findings of dysphagia in patients with Parkinson's disease, using videofluoroscopic study
S. H. Lim, Kyungki-Do, Republic of Korea
- OP-2-02** Validity of the 5-item clock-drawing scoring system in screening of dementia in Parkinson's disease patients
C. Tangkanakul, Pathumthani, Thailand
- OP-2-03** Depression and executive functions modulate motor-related brain activity in parkinsonians
J. Yan, Shenzhen, China
- OP-2-04** LRRK2 variant is associated with lower risk of essential tremor
S. H. Ng, Singapore, Singapore
- OP-2-05** Prevalence of cerebral and cardiovascular disease in Parkinson's disease patients: a meta-analysis
C. T. Hong, New Taipei City, Taiwan
- OP-2-06** White matter alterations in Parkinson's disease with normal cognition precede grey matter atrophy
I. Rektor, Brno, Czech Republic
- OP-2-07** Epidemiology of Parkinson's disease in Africa: challenges and opportunities
D. Gams Massi, Dakar, Senegal
- OP-2-09** Depression in Parkinson's disease: a case-control study
M.-H. Chang, Taichung, Taiwan
- OP-2-10** Motor symptom laterality affects acquisition in Parkinson's disease: a cognitive and functional magnetic resonance imaging study
P. Huang, Shanghai, China
- OP-2-11** Putaminal dopamine depletion patterns in de novo Parkinson's disease predict later development of motor complication types
Y. H. Sohn, Seoul, Republic of Korea
- OP-2-12** Variants in MCCC1/LAMP3 and DGKQ identified through GWAS are not associated with PD in a Malaysian Malay cohort
J. L. Lim, Kuala Lumpur, Malaysia

- OP-2-13 The modifying effect of age on survival in Parkinson's disease: big data analysis
C. Peretz, Tel Aviv, Israel
- OP-2-14 Association between serum uric acid levels and disease severity in Parkinson patients
P. To Thi Bich, Nha Trang City, Vietnam
- OP-2-15 Apathy in drug-naïve patients with Parkinson's disease
H. Liu, Chengdu, China
- OP-2-16 Cardinal symptoms of Parkinson's disease cohabit with levodopa-induced dyskinesia
E. Goubault, Montréal, Canada
- OP-2-17 The association of perceived stress and the frequency and severity of non-motor symptoms in Parkinson's disease
M. Cusso, Southport, Australia

08:30 – 10:00 **Focusing on New Targets for Therapy** **Room Castor 1**

Chair: T. Simuni, Chicago, United States

Learning Objectives

- To discuss the glucocerebrosidase (GBA) gene and its potential as a therapeutic target
- To discuss glucagon-like peptide -1 and its potential as a therapeutic target
- To discuss alpha synuclein antibodies as therapies

08:30 – 09:00 Spotlight on Glucocerebrosidase
W. Le, Dalian, China

09:00 – 09:30 Spotlight on Glucagon-Like Peptide-1
S. Fujioka, Fukuoka, Japan

09:30 – 10:00 Spotlight on the Alpha Synuclein Antibodies
L. Kalia, Toronto, Canada

08:30 – 10:00 **Is Parkinson Disease a Prion Disease?** **Room Castor 2**

Chair: F. Valldeoriola, Barcelona, Spain

Learning Objectives

- To understand the evidence for and against the hypothesis that Parkinson disease is a prion disease

08:30 – 09:00 Yes – Parkinson Disease is a Prion Disease!
W. Meissner, Bordeaux, France

SCIENTIFIC PROGRAM

MONDAY
13 November 2017

09:00 – 09:30 No – Parkinson Disease is NOT a Prion Disease!
J. Surmeier, Chicago, United States

09:30 – 09:45 Debate

09:45 – 10:00 Question and Answer

08:30 – 10:00 **Autonomic Dysfunction in Parkinson Disease** **Room Pollux 1**



*Chair: R. Pfeiffer, Portland, United States
H. T. Nguyen, Hanoi, Vietnam*

Learning Objectives

- To characterize cardiovascular dysfunction in Parkinson disease
- To characterize gastrointestinal complications in Parkinson disease
- To characterize urogenital issues in Parkinson disease

08:30 – 09:00 Cardiovascular Dysfunction in Parkinson Disease
H. Kaufmann, New York, United States

09:00 – 09:30 Gastrointestinal Complications in Parkinson Disease
A. Melo, Salvador, Brazil

09:30 – 10:00 Urogenital Issues in Parkinson Disease
K. Frei, Loma Linda, United States

In collaboration with evidentia.med

08:30 – 10:00 **Treating the Most Challenging Behavioral and Cognitive Issues in Parkinson Disease** **Room Castor 3**



Chair: H.-F. Shang, Chengdu, Sichuan, China

Learning Objectives

- To understand the evolution of the treatment of psychosis in Parkinson disease
- To describe the history and treatment of impulse control behavior disorders in Parkinson disease
- To explain the challenges associated with dementia and its treatment in Parkinson disease

08:30 – 09:00 The Evolution of Parkinson Disease Psychosis Treatment
D. Weintraub, Philadelphia, United States

09:00 – 09:30 The Rise and Fall of Impulse Control Behavior Disorders
C. Colosimo, Terni, Italy

09:30 – 10:00 Facing the Challenges When Dementia Sets In
M. Lew, Los Angeles, United States

08:30 – 10:00



Neuropathology and Behavioral Dysfunction in Parkinson Disease

**Room
Pollux 2**

Chair: S. Isaacson, Boca Raton, United States

Learning Objectives

- To describe the neuropathology of Parkinson disease
- To characterize symptoms of fatigue, apathy, and depression in Parkinson disease
- To outline the similarities and differences of Parkinson disease dementia (PDD) and dementia with Lewy bodies

08:30 – 09:00

Neuropathology of Parkinson Disease
D. Dickson, Jacksonville, United States

09:00 – 09:30

Fatigue, Apathy and Depression in Parkinson Disease
J. Friedman, Rhode Island, United States

09:30 – 10:00

The Overlapping Syndromes of Parkinson Disease Dementia and Dementia With Lewy Bodies
I. Rektorova, Brno, Czech Republic

In collaboration with evidentia.med

10:30 – 12:00



Understanding the Complex Web of Cognitive Dysfunction and Movement Disorders

Plenary

*Chair: E.-K.Tan, Singapore, Singapore
P. Riederer, Wuerzburg, Germany*

Learning Objectives

- To identify the scope of cognitive dysfunction in movement disorders
- To describe the tauopathies and the link between aggregated tau protein and cognitive dysfunction
- To describe cognitive dysfunction and movement disorders in adult-onset leukoencephalopathies

10:30 – 11:00

The Spectrum of Mild Cognitive Impairment to Dementia in Parkinson Disease
D. Weintraub, Philadelphia, United States

11:00 – 11:30

Untangling the Tauopathies
H. Ling, London, United Kingdom

11:30 – 12:00

Cognitive Dysfunction and Movement Disorders in Adult-Onset Leukoencephalopathies
T. Ikeuchi, Niigata, Japan

SCIENTIFIC PROGRAM

MONDAY
13 November 2017

12:00 – 13:30	Corporate Session 2 (see page 112)	Room Castor 1
13:30 – 15:00	The Treatment of Parkinson Disease: 200 Years Later	Plenary
	<p><i>Chair: B. Jeon, Seoul, Republic of Korea</i> <i>S.-D. Chen, Shanghai, China</i></p> <p>Learning Objectives</p> <ul style="list-style-type: none"> • To describe the current pharmacotherapy of Parkinson disease • To understand the current surgical treatments for Parkinson disease • To explain the principal non-pharmacological therapies for Parkinson disease 	
13:30 – 14:00	Pharmacological Advances in Parkinson Disease Treatment	
	<i>F. Stocchi, Rome, Italy</i>	
14:00 – 14:30	The Current State of Functional Neurosurgical Therapy in Parkinson Disease	
	<i>E. Moro, Grenoble, France</i>	
14:30 – 15:00	The Most Promising Non-Pharmacological Therapies for Parkinson Disease	
	<i>B. Bloem, Nijmegen, The Netherlands</i>	
15:30 – 17:00	Focusing on Gut Microbiota	Room Castor 1
	<p><i>Chair: I. Bodis-Wollner, Brooklyn, United States</i> <i>P. Pal, Bengaluru, Karnataka, India</i></p> <p>Learning Objectives</p> <ul style="list-style-type: none"> • To explain gastrointestinal dysfunction and pathology in Parkinson disease • To identify the major findings of gastrointestinal biopsy studies in Parkinson disease • To describe future challenges in understanding the gut microbiota in Parkinson disease 	
15:30 – 16:00	Past: Historical Overview and the Pathology of Gastrointestinal Dysfunctions in Parkinson Disease	
	<i>A. Melo, Salvador, Brazil</i>	
16:00 – 16:30	Present: What We Have Learned from Gastrointestinal Biopsy Studies in Parkinson Disease?	
	<i>K. Shannon, Madison, United States</i>	
16:30 – 17:00	Future Perspectives: The Enteric Glia, Small Intestinal Bacterial Overgrowth, and Microbiota in Parkinson Disease	
	<i>R. Cilia, Milano, Italy</i>	

15:30 – 17:00	<p>Are SPECT Scans Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders?</p> <p><i>Chair: M. Lew, Los Angeles, United States</i></p> <p>Learning Objectives</p> <ul style="list-style-type: none"> To appreciate the pros and cons of using SPECT scans for diagnosis of Parkinson and related diseases 	<p>Room Castor 2</p>
15:30 – 16:00	<p>Yes: SPECT Scans are Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders!</p> <p><i>A. Antonini, Venice, Padova, Italy</i></p>	
16:00 – 16:30	<p>No: SPECT Scans are NOT Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders!</p> <p><i>J. Stoessl, Vancouver, Canada</i></p>	
16:30 – 16:45	Debate	
16:45 – 17:00	Question and Answer	
15:30 – 17:00	<p>Meet the Professor 2</p> <p><i>Professor: S. Fahn, New York, United States</i></p>	<p>Meet the Professor Lounge (Exhibition)</p>
15:30 – 17:00	<p>Skills Workshop 1: Deep Brain Stimulation Surgery</p> <p><i>Chair: J. Krauss, Hannover, Germany T. Bruecke, Vienna, Austria</i></p> <p>Learning Objectives</p> <ul style="list-style-type: none"> To define the optimal patient characteristics for deep brain stimulation To learn tips for deep brain stimulation programming To identify and manage complications of deep brain stimulation 	<p>Room Pollux 1</p>
15:30 – 15:55	<p>The Ideal Patient for Deep Brain Stimulation Surgery</p> <p><i>E. Moro, Grenoble, France</i></p>	
15:55 – 16:20	<p>Pearls and Pitfalls in Deep Brain Stimulation Programming</p> <p><i>J. Jimenez-Shahed, Houston, United States</i></p>	
16:20 – 16:45	<p>Managing Complications in Deep Brain Stimulation</p> <p><i>J. Aguilar, Metro Manila, Philippines</i></p>	
16:45 – 17:00	Practical Demonstration	

SCIENTIFIC PROGRAM

MONDAY
13 November 2017

15:30 – 17:00	Are We Ready for Digital Technology in the Assessment and Management of Parkinson Disease?	Room Castor 3
	<i>Chair: R. Bhidayasiri, Bangkok, Thailand</i>	
	Learning Objectives	
	<ul style="list-style-type: none">• To summarize the benefits and drawbacks of traditional outcome measures in Parkinson disease• To understand the uses of digital technology as clinical trial outcome measures• To explain the benefits of wearable sensors in treating Parkinson disease	
15:30 – 16:00	Historical Perspective: The Pros and Cons of Conventional Outcome Measures in Parkinson Disease <i>S.-Y. Lim, Kuala Lumpur, Malaysia</i>	
16:00 – 16:30	The Present: The Invasion of Digital Technology in Parkinson Clinical Trials <i>A. Espay, Cincinnati, United States</i>	
16:30 – 17:00	The Future: How Wearable Sensors Can Transform Parkinson Management <i>E. Van Wegen, Amsterdam, The Netherlands</i>	
15:30 – 17:00	Therapy for Parkinson Disease Part I	Room Pollux 2
	<i>Chair: A. Friedman, Warsaw, Poland</i>	
	Learning Objectives	
	<ul style="list-style-type: none">• To describe current medications for the treatment of Parkinson disease• To explain the management of medication-induced motor side effects in the treatment of Parkinson disease• To explain the management of medication-induced cognitive and behavioral side effects in the treatment of Parkinson disease	
15:30 – 16:00	Current Conventional Pharmacotherapeutical Interventions <i>R. Pahwa, Kansas City, United States</i>	
16:00 – 16:30	Addressing Motor Pharmacotherapeutical Complications in Parkinson Disease <i>T. Mueller, Berlin, Germany</i>	
16:30 – 17:00	Addressing the Cognitive and Behavioral Pharmacotherapeutical Complications of Parkinson Disease <i>S. Isaacson, Boca Raton, United States</i>	
	<i>In collaboration with evidentia.med</i>	

OP-3
15:30 – 17:00

Oral Poster Session 3
Parkinson 1: Etiology/ Epidemiology/ Pathophysiology
(4 minutes oral presentation followed by 2 minutes Q&A)

**Poster
Exhibition**

*Chair: I. Rektorova, Brno, Czech Republic
I. Isaias, Wuerzburg, Germany*

- OP-3-01** Objective versus subjective assessments of freezing of gait: An observational study of patients with Parkinson's disease and related disorders in Singapore
S. Y. Nicole Chia, Singapore, Singapore
- OP-3-02** Oral health of Parkinson's disease patients, a case-control study
C. de Baat, Oegstgeest, The Netherlands
- OP-3-03** Rare GCH1 heterozygous variants contributing to Parkinson's disease
J. Guo, Changsha, China
- OP-3-04** Rapid eye movement behavior disorder in drug-naïve patients with Parkinson's disease
H. Liu, Chengdu, China
- OP-3-05** Patients and their caregivers' burdens for Parkinson's disease in Korea
J. S. Baik, Seoul, Republic of Korea
- OP-3-06** Greater motor progression in patients with Parkinson disease who carry Park 16 variant
X. Deng, Nanning, China
- OP-3-08** The association between early treatment with amantadine and delayed onset of levodopa-induced dyskinesia in patients with Parkinson's disease
T. L. Wu, Taipei, Taiwan
- OP-3-09** Clinical features and life quality in normosmic Parkinson's disease
S. Cui, Shanghai, China
- OP-3-10** Glucocerebrosidase gene mutation in Parkinson's disease
M. Macas, Manila, Philippines
- OP-3-11** Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease
J. Kim, Gwanju, Republic of Korea
- OP-3-12** Comorbid conditions associated with Parkinson's disease: a population-based study from the Nebraska Parkinson's Disease Registry
J. Bertoni, Omaha, United States

SCIENTIFIC PROGRAM

MONDAY
13 November 2017

- OP-3-13** Reduced arm swing during gait in patients with Parkinson disease: objective motion analysis study
Y. M. Park, Seoul, Republic of Korea
- OP-3-14** Body composition, sarcopenia and frailty in a multi-ethnic Asian cohort with Parkinson's disease
A. H. Tan, Kuala Lumpur, Malaysia
- OP-3-15** Diagnostic value of striatal-prefrontal projection estimated by cerebral blood flow and dopamine transporter SPECT in Parkinsonian syndromes
Y. Nakano, Chiba, Japan
- OP-3-16** Pain in Parkinson disease: a local single-center correlational study of ambulatory Parkinson disease patients
M. A. C. Sy, Manila, Philippines

17:15 – 18:45



IAPRD Annual General Meeting

Chair: D. Truong, Fountain Valley, United States

Plenary

Access for Full IAPRD Members.

PROGRAM OVERVIEW

TUESDAY
14 November 2017

Room	Plenary	Room „Pollux 1“	Room „Pollux 2“	Room „Castor 1“	
08:00					
08:30		Therapy for Parkinson Disease Part II	Phenomenology of Movement Disorders	Focusing on the Multidisciplinary Approach to Parkinson Disease and Other Movement Disorders	
09:00					
09:30					
10:00	Coffee Break				
10:30	Revisiting the Classical Motor Disorders Impacting the Globe				
11:00					
11:30					
12:00	Lunch Break			Corporate Session 3	
12:30					
13:00					
13:30	When Lightning Strikes Twice: Finding the Balance Between Motor Symptoms and Behavior in 3 Complex Movement Disorders				
14:00					
14:30					
15:00	Coffee Break				
15:30		Tremors	Vietnamese Movement Disorder Session	The Painful Truth About Pain in Movement Disorders	
16:00					
16:30					
17:00	Coffee Break				
17:30	Skills Workshop 2: Botulinum Toxin Injections	Dystonia and Sleep Related Movement Disorders	Parkinson Plus Syndromes	Essential Tremor: Reflecting on the Past and Leaping into the Future	
18:00					
18:30					
19:00					

 Plenary Sessions

 Point-Counterpoint Interactive Session

 Timeline Parallel Session

 Clinical Practice Session

Tuesday, 14 November 2017

TUESDAY
14 November 2017







Room „Castor 2“	Room „Castor 3“	Poster Exhibition	Meet the Professor Lounge (Exhibition)
-----------------	-----------------	-------------------	--

Deep Brain Stimulation in Early Parkinson Disease: Is it Ready for Prime Time?	Dystonia: Past, Present and Future	Oral Poster Session 4
--	------------------------------------	-----------------------

Lunch Break	Corporate Session 4	Lunch Break
-------------	---------------------	-------------

Parade of Movement Disorders From Around the Globe	Past, Present and Future of Huntington Disease Care	Oral Poster Session 5 - Nominees for Best Poster	Meet the Professor 3 Mark Hallett
--	---	--	-----------------------------------


The Pearls and Pitfalls of Psychogenic Movement Disorders	Autoimmune Movement Disorders: Current Understanding and Future Directions	Oral Poster Session 6
---	--	-----------------------

-  Pho Hot Topic Session
-  Corporate Session
-  Skills Workshop
-  Meet the Professor
-  Oral Poster Session
-  Global Video Session

SCIENTIFIC PROGRAM

TUESDAY
14 November 2017

08:30 – 10:00	Focusing on the Multidisciplinary Approach to Parkinson Disease and Other Movement Disorders	Room Castor 1
	<i>Chair: D. Torres-Russotto, Omaha, United States T. Le, Ho Chi Minh City, Vietnam</i>	
	Learning Objectives	
	<ul style="list-style-type: none">• To learn about the importance of rehabilitation and exercise in Parkinson disease• To describe treatment of sexual dysfunction in movement disorders• To understand the importance of nutrition in Parkinson disease	
08:30 – 09:00	Run, Pedal, Stretch: The Inevitable Role of Rehabilitation and Exercise in Parkinson Disease <i>J. Alberts, Cleveland, United States</i>	
09:00 – 09:30	Bedtime Stories: Addressing Sexual Dysfunction in Movement Disorders <i>C. Singer, Miami, United States</i>	
09:30 – 10:00	The Most Relevant Nutritional Issues in Parkinson Disease <i>E. Cereda, Pavia, Italy</i>	
08:30 – 10:00	Deep Brain Stimulation in Early Parkinson Disease: Is it Ready for Prime Time?	Room Castor 2
	<i>Chair: J.-P. Azulay, Marseille, France T. Tran, Ho Chi Minh City, Vietnam</i>	
	Learning Objectives	
	<ul style="list-style-type: none">• To understand the pros and cons of deep brain stimulation for early Parkinson disease	
08:30 – 09:00	Deep Brain Stimulation in Early Parkinson Disease: It is Ready for Prime Time! <i>M. Tagliati, Los Angeles, United States</i>	
09:00 – 09:30	Deep Brain Stimulation in Early Parkinson Disease: It is NOT Ready for Prime Time! <i>B. Jeon, Seoul, Republic of Korea</i>	
09:30 – 09:45	Debate	
09:45 – 10:00	Question and Answer	

08:30 – 10:00  **Therapy for Parkinson Disease Part II** **Room Pollux 1**

*Chair: Y.-R. Wu, Taoyuan, Taiwan
T. Le, Ho Chi Minh City, Vietnam*

Learning Objectives


- To describe non-pharmacologic treatments for Parkinson disease
- To understand the role of medications that continuously stimulate the dopaminergic system in Parkinson disease
- To explain the use of surgical interventions such as deep brain stimulation in Parkinson disease

08:30 – 09:00 Non-Pharmacotherapeutical Interventions in Parkinson Disease
J. Bajwa, Riyadh, Saudi Arabia

09:00 – 09:30 The Role of Continuous Dopaminergic Stimulation in Parkinson Disease
A. Antonini, Venice, Italy

09:30 – 10:00 Surgical Interventions in Parkinson Disease
J. Krauss, Hannover, Germany

In collaboration with evidentia.med

08:30 – 10:00  **Phenomenology of Movement Disorders** **Room Pollux 2**

Chair: R. Rosales, Quezon City, Philippines


Learning Objectives

- To recognize the clinical signs of hypokinesia
- To recognize the clinical signs of hyperkinesia
- To recognize the clinical signs of less common movement disorders

08:30 – 09:00 The Most Relevant Hypokinetic Disorders
R. Rodriguez, Gainesville, United States

09:00 – 09:30 Hyperkinetic Disorders Everyone Needs to Recognize
S.-Y. Lim, Kuala Lumpur, Malaysia

09:30 – 10:00 The Most Unusual and Fascinating Movement Disorders
R. Bhidayasiri, Bangkok, Thailand

08:30 – 10:00  **Dystonia: Past, Present and Future** **Room Castor 3**

Chair: H. Jinnah, Atlanta, United States

SCIENTIFIC PROGRAM

TUESDAY
14 November 2017

Learning Objectives

- To understand the history of dystonia
- To learn the pathophysiology of dystonia and current treatment options
- To outline recent dystonia findings and potential future treatments

- 08:30 – 09:00 The Colorful History of Dystonia
D. Dressler, Hannover, Germany
- 09:00 – 09:30 The Pathophysiology of Dystonia and Its Current Treatment
H. Jinnah, Atlanta, United States
- 09:30 – 10:00 The Most Promising Advances and Future Treatments
M. Vidailhet, Paris, France

08:30 – 10:00	OP-4 Oral Poster Session 4 Parkinson 2: Treatment <i>(4 minutes oral presentation followed by 2 minutes Q&A)</i>	Poster Exhibition
■	<i>Chair: W. Meissner, Bordeaux, France</i> <i>J. Jimenez-Shahed, Houston, United States</i>	
OP-4-01	Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study <i>G. Pezzoli, Pavia, Italy</i>	
OP-4-03	Physical activity and its impact on non-motor aspects of Parkinson's disease – the early Parkinson's disease Longitudinal Singapore (PALS) study <i>Y. E. Samuel Ng, Singapore, Singapore</i>	
OP-4-04	Beneficial effect of laughter yoga and clapping exercise in Parkinson's disease patients in south Delhi metro population <i>V. Sharma, New Delhi, India</i>	
OP-4-05	Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in subjects with Parkinson's disease: preliminary results from the Phase 3 study dose-titration phase <i>A. Espay, Cincinnati, United States</i>	
OP-4-06	Depression in Parkinson's disease: relation with the level of "given up" activities <i>S. Bogard, Montréal, Canada</i>	
OP-4-07	Long-term efficacy of inhaled levodopa in Parkinson's disease subjects with motor fluctuations: interim results of a phase 3 study <i>C. Oh, Ardsley, United States</i>	

- OP-4-08 Pooled analysis of phase 3 studies of ADS-5102 for levodopa-induced dyskinesia: A detailed review of MDS-UPDRS, part IV (motor complications)
C. Tanner, San Francisco, United States
- OP-4-09 The influence of smell and taste disturbances on the nutritional status in Parkinson disease
M. Koszewicz, Wroclaw, Poland
- OP-4-10 Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06649751, an oral dopamine D1/D5 agonist, in Parkinson's disease: a single ascending dose study
D. Gray, Cambridge, United States
- OP-4-11 Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral dopamine D1/D5 agonist PF-06649751 in Parkinson's disease: a multiple ascending dose study
D. Gray, Cambridge, United States
- OP-4-12 Therapeutic effect of non-invasive vagus nerve stimulation in gait disturbance and freezing in Parkinson's disease patients
B. Mondal, Kolkata, India
- OP-4-13 The availability of anti-parkinsonian drugs in Thailand and associated factors
K. Sakdisornchai, Bangkok, Thailand
- OP-4-14 Value of intraoperative neurophysiological monitoring for clinical outcome of deep brain stimulation of subthalamic nucleus in Parkinson's disease
A. Gamaleya, Moscow, Russian Federation
- OP-4-15 A naturalistic observation on 20 consecutive patients under LCIG at the "Tor Vergata" University; enforced counseling and alternative route of LD delivery for avoiding discontinuation?
A. Stefani, Rome, Italy

10:30 – 12:00

Revisiting the Classical Motor Disorders Impacting the Globe

Plenary

*Chair: R. Borgohain, Hyderabad, India
R. Bhidayasiri, Bangkok, Thailand*

Learning Objectives

- To describe parkinsonism, its variation around the globe, and treatment evolution
- To describe dystonia, its variation around the globe, and treatment evolution
- To describe tremor, its variation around the globe, and treatment evolution

SCIENTIFIC PROGRAM

TUESDAY
14 November 2017

10:30 – 11:00	Parkinsonism: Then and Now <i>F. Stocchi, Rome, Italy</i>	
11:00 – 11:30	Dystonia: Then and Now <i>C. Comella, Chicago, United States</i>	
11:30 – 12:00	Tremor: Then and Now <i>E. Louis, New Haven, United States</i>	
12:00 – 13:30	Corporate Session 3 (see page 113)	Room Castor 1
12:00 – 13:30	Corporate Session 4 (see page 113)	Room Castor 3
13:30 – 15:00	When Lightning Strikes Twice: Finding the Balance Between Motor Symptoms and Behavior in 3 Complex Movement Disorders	Plenary
	<i>Chair: C. Comella, Chicago, United States D. Truong, Fountain Valley, USA</i>	
	Learning Objectives	
	<ul style="list-style-type: none"> • To understand the pathology, clinical characteristics, and treatment of Huntington disease • To understand the pathology, clinical characteristics, and treatment of Tourette Syndrome • To understand the clinical characteristics and treatment of psychogenic movement disorders 	
13:30 – 14:00	Huntington Disease: What We Have Learned Since the Gene was Discovered <i>J. Jankovic, Houston, United States</i>	
14:00 – 14:30	The Colorful Spectrum of Tourette Syndrome and Its Medical, Surgical and Behavioral Therapies <i>J. Roth, Praha, Czech Republic</i>	
14:30 – 15:00	The Most Promising Advances in our Understanding and Treatment of Psychogenic Movement Disorders <i>M. Hallett, Bethesda, United States</i>	
15:30 – 17:00	Parade of Movement Disorders from Around the Globe	Room Castor 2
	<i>Chair: H. Fernandez, Cleveland, United States</i>	
	Learning Objectives	
	<ul style="list-style-type: none"> • To understand common movement disorders in Asia • To understand common movement disorders in South America • To understand common movement disorders in Africa 	

15:30 – 16:00 Movement Disorders in Asia
T. T. Lim, George Town, Malaysia

16:00 – 16:30 Movement Disorders in South America
O. Bernal-Pacheco, Bogotá, Colombia

16:30 – 17:00 Movement Disorders in Africa
O. Ojo, Lagos, Nigeria

15:30 – 17:00 **The Painful Truth About Pain in Movement Disorders** **Room
Castor 1**

Chair: M. Relja, Zagreb, Croatia

Learning Objectives

- To describe the clinical methods for evaluating pain in movement disorders
- To outline the assessment and treatment of pain in Parkinson disease
- To outline the assessment and treatment of pain in hyperkinetic disorders

15:30 – 16:00 The Clinical Assessment of Pain in Movement Disorders
H. Reichmann, Dresden, Germany

16:00 – 16:30 The Approach to Pain in Parkinson Disease
R. Rosales, Quezon City, Philippines

16:30 – 17:00 When Movement Disorders Hurt: Addressing Pain in Hyperkinetic Disorders
M. Relja, Zagreb, Croatia

15:30 – 17:00 **Past, Present and Future of Huntington Disease Care** **Room
Castor 3**

*Chair: K. Shannon, Madison, United States
G. Rakhimbaeva, Taskent, Uzbekistan*

Learning Objectives

- To describe the evolution of Huntington disease care
- To understand the multidisciplinary care of Huntington disease at treatment centers
- To explain the potential benefits and drawbacks of deep brain stimulation surgery for Huntington disease

SCIENTIFIC PROGRAM

TUESDAY
14 November 2017

- 15:30 – 16:00 Huntington Disease Care: From the Past to the Present
T. Mestres, Ottawa, Canada
- 16:00 – 16:30 The Current and Emerging Trends of Huntington Disease Care at Multidisciplinary Centers
K. Shannon, Madison, United States
- 16:30 – 17:00 Is There a Role for Deep Brain Stimulation Surgery in Huntington Disease?
J.-P. Azulay, Marseille, France

15:30 – 17:00 **Tremors** **Room Pollux 1**

Chair: W. Ondo, Houston, United States

Learning Objectives

- To describe the pathophysiology of tremor
- To describe the clinical aspects of tremor
- To outline the treatment strategies for tremor

15:30 – 16:00 Tremor: Pathophysiology
R. Helmich, Nijmegen, The Netherlands

16:00 – 16:30 Tremor: Clinical Aspects
C. Diesta, Quezon City, Philippines

16:30 – 17:00 Tremor: Treatment
C. Singer, Miami, United States

In collaboration with evidentia

15:30 – 17:00 **Meet the Professor 3** **Meet the Professor Lounge (Exhibition)**
Professor: M. Hallett, Bethesda, United States

OP-5 **Oral Poster Session 5** **Poster Exhibition**
15:30 – 17:00 **The TOP Presentations – Nominees for Best Poster**
(4 minutes oral presentation followed by 2 minutes Q&A)

*Chair: C. Baumann, Zurich, Switzerland
E. Moro, Grenoble, France*

OP-5-01 Evaluation of various movement disorders in patients of genetically proven spinocerebellar ataxia: a study from a tertiary care center in northern India
D. Madathiparambil Radhakrishnan, Delhi, India

OP-5-02 Impaired freeze response in psychogenic (functional) movement disorder patients during exposure to stress
S. Aybek, Bern, Switzerland

- OP-5-03 MicroRNA-4639 is a regulator of DJ-1 expression and a potential diagnostic marker for early Parkinson's disease
Y. Chen, Shanghai, China
- OP-5-04 Chronic *Mucuna pruriens* in Parkinson's disease: a non-inferiority, randomised, crossover, phase-2b trial
R. Cilia, Milan, Italy
- OP-5-05 Visual spatial dysfunction and retinal nerve fiber layer thickness in patients with Parkinson disease
P. C. Teh, Wilayah Persekutuan Kuala Lumpur, Malaysia
- OP-5-06 Turn cranio-caudal signature assessment from inertial systems for mobility deficit identification in Parkinson's disease patients
K. Lebel, Sherbrooke, Canada
- OP-5-07 Long term results of the VANTAGE study: a prospective multicenter trial evaluating deep brain stimulation with a multiple source, constant current system in Parkinson's disease
T. Bruecke, Vienna, Austria
- OP-5-08 Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease
D. K. Ness, South San Francisco, United States
- OP-5-09 An electrical muscle stimulation therapy for intractable tremor in Parkinson's disease: a randomized sham-controlled trial of a tremor's glove device
O. Jitkriksadakul, Bangkok, Thailand
- OP-5-11 Zonisamide improves parkinsonism in Dementia with Lewy Bodies (DLB): a randomized double-blind placebo-controlled Phase 3 study
K. Hasegawa, Sagamihara, Japan
- OP-5-12 Cooperative synthesis of dopamine by striatal non-dopaminergic neurons as a mechanism of neuroplasticity at parkinsonism
A. Kim, Moscow, Russian Federation
- OP-5-13 Effects of once-daily valbenazine on tardive dyskinesia by body region
S. Siegert, San Diego, United States
- OP-5-14 Safety and efficacy of daxibotulinumtoxinA for injection (RT002) in cervical dystonia (CD): results of a phase 2, dose escalating study
D. Truong, Fountain Valley, United States
- OP-5-15 Video amplification as a sensitive screening tool for orthostatic tremor
D. Torres-Russotto, Omaha, United States

SCIENTIFIC PROGRAM


TUESDAY
14 November 2017

15:30 – 17:00	Vietnamese Movement Disorder Session	Room Pollux 2
	<p><i>Chair: M. Le, Ho Chi Minh City, Vietnam</i> <i>H. C. Nguyen, Ho Chi Minh City, Vietnam</i></p>	
15:30 – 15:41	Report on the Activity of a Movement Disorder Unit at the Teaching Hospital University Medical Center <i>N. T. Tran, Ho Chi Minh City, Vietnam</i>	
15:41 – 15:52	Botulinum Neurotoxin A for the Treatment of Cervical Dystonia: A 5-Year Case Series Study <i>N. T. Tran, Ho Chi Minh City, Vietnam</i>	
15:52 – 16:03	Early Onset Parkinson Disease in Vietnamese Patients: An Initial Study <i>V. L. Nguyen, Hanoi, Vietnam</i>	
16:03 – 16:14	Cognitive Impairment and Dementia in Vietnamese Parkinsonian Patients: A Prevalence Study <i>C. T. Tran, Ho Chi Minh City, Vietnam</i>	
16:14 – 16:25	Depression in Parkinson Disease: An Initial Study with the Beck Depression Inventory <i>T. B. Nguyen, Hanoi, Vietnam</i>	
16:25 – 16:36	Deep Brain Stimulation for Parkinson Disease and other Movement Disorders in Vietnamese Patients: Initial Results <i>A. T. Pham, Ho Chi Minh City, Vietnam</i>	
16:36 – 16:47	Case Report of Neuroacanthocytosis in Vietnam <i>N. N. T. Vo, Ho Chi Minh City, Vietnam</i>	
16:47 – 16:58	Mitochondrial-Membrane Protein-Associated Neurodegeneration (MPAN): A Case Report <i>T. H. T. Dang, Ho Chi Minh City, Vietnam</i>	
OP-6	Oral Poster Session 6	Poster Exhibition
17:30 – 19:00	Parkinsonian Syndromes / Behavior and Cognition <i>(4 minutes oral presentation followed by 2 minutes Q&A)</i>	
	<p><i>Chair: Y.-R. Wu, Taoyuan, Taiwan</i> <i>T. Mestre, Ottawa, Canada</i></p>	
OP-6-01	Cognitive impairment in Parkinson's disease: correlation with apolipoprotein E genetic polymorphism and plasma a-synuclein <i>N. A. Samat, Cheras, Malaysia</i>	
OP-6-02	LRRK2 GTPase domain variants in dementia <i>X. J. Zhang, Singapore, Singapore</i>	

- OP-6-03** Clinical and cardiac autonomic profile of parkinsonian and cerebellar phenotypes of probable multiple system atrophy
M. R. Rukmani, Bangalore, India
- OP-6-04** Novel POLG mutation in a patient with early-onset parkinsonism, progressive external ophthalmoplegia and optic atrophy
L. Ma, Beijing, China
- OP-6-05** Impulse control disorder frequency in different parkinsonism syndromes
M. Akbostanci, Ankara, Turkey
- OP-6-06** Color vision impairment in dementia with Lewy bodies and prodromal Lewy bodies, a simple distinguishing feature from Alzheimer's dementia and prodromal Alzheimer's disease
B. Tousi, Cleveland, United States
- OP-6-07** Impact of frontal lobe function and behavioral changes on quality of life in patients with multiple system atrophy
L. Zhang, Chengdu, China
- OP-6-08** Analysis of GWAS-linked variants in multiple system atrophy
X. Gu, Chengdu, China
- OP-6-09** Association analysis of SNP rs11868035 in SREBF1 with Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population
X. Yuan, Chengdu, China
- OP-6-10** Diagnostic markers in the pathogenesis of parkinsonism syndrome development in chronic brain ischemia
K. Khajibakiev, Tashkent, Uzbekistan
- OP-6-11** Autonomic function tests in Parkinson's disease and multiple system atrophy
T. Vo Nguyen Ngoc, Ho Chi Minh, Vietnam
- OP-6-12** Comparison of gait parameters between drug-naive patients with multiple system atrophy with predominant parkinsonism and Parkinson's disease
B. S. Na, Seoul, Republic of Korea
- OP-6-13** Interrelationships between survival, sex and blood pressure in patients with multiple system atrophy
C. Peretz, Tel Aviv, Israel
- OP-6-14** CSF biological markers of neurodegeneration in patients with Lewy Body Disease (LBD) and Progressive Supranuclear Palsy (PSP)
M. Frolova, Olomouc, Czech Republic

SCIENTIFIC PROGRAM

TUESDAY
14 November 2017

17:30 – 19:00  **The Pearls and Pitfalls of Psychogenic Movement Disorders** **Room Castor 2**

Chair: P. Pal, Bengaluru, Karnataka, India


Learning Objectives

- To recognize and diagnose psychogenic movement disorders
- To recognize organic movement disorders that appear psychogenic
- To recognize psychogenic movement disorders that appear organic

17:30 – 18:00 The Diagnosis and Clinical Manifestations of Psychogenic Movement Disorders
S. Fahn, New York, United States

18:00 – 18:30 Organic Movement Disorders that Appear Psychogenic
X. X. Yu, Cleveland, United States

18:30 – 19:00 Psychogenic Movement Disorders that Appear Organic
A. Espay, Cincinnati, United States

17:30 – 19:00  **Essential Tremor: Reflecting on the Past, and Leaping into the Future** **Room Castor 1**

*Chair: I. Isaias, Wuerzburg, Germany
S. Kamenova, Almaty, Kazakhstan*


Learning Objectives

- To characterize the signs and diagnosis of essential tremor and its evolution over time
- To analyze the contribution of genetic and environmental factors to essential tremor
- To describe current and potential future treatments for essential tremor

17:30 – 18:00 The Evolving Definition of Essential Tremor
E. Louis, New Haven, United States

18:00 – 18:30 The Etiology of Essential Tremor: Genes versus Environment
R. Helmich, Nijmegen, The Netherlands

18:30 – 19:00 Treating Essential Tremor: The Current and Most Promising Therapies
R. Pahwa, Kansas City, United States

17:30 – 19:00  **Dystonia and Sleep Related Movement Disorders** **Room Pollux 1**

*Chair: D. Dressler, Hannover, Germany
T. Nguyen Vo, Ho Chi Minh City, Vietnam*

Learning Objectives

- To describe the pathophysiology and classification of dystonia
- To outline the signs, symptoms, and treatment of dystonia
- To summarize sleep-related movement disorders and their treatment

17:30 – 18:00 Dystonia: Pathophysiology / Classification
J. Jimenez-Shahed, Houston, United States

18:00 – 18:30 Dystonia: Clinical Aspects / Treatment
D. Dressler, Hannover, Germany

18:30 – 19:00 Sleep-Related Movement Disorders
C. Baumann, Zurich, Switzerland

In collaboration with evidentia.med

17:30 – 19:00 **Autoimmune Movement Disorders: Current Understanding and Future Directions** **Room Castor 3**

Chair: R. Mridula, Panjagutta, India

Learning Objectives

- To understand immune-mediated autoimmune movement disorders and their treatment
- To understand paraneoplastic autoimmune movement disorders and their treatment
- To understand non-paraneoplastic autoimmune movement disorders and their treatment

17:30 – 18:00 Infection-Mediated Autoimmune Movement Disorders
A. DiRocco, New York, United States

18:00 – 18:30 Paraneoplastic Autoimmune Movement Disorders
T. T. Lim, George Town, Malaysia

18:30 – 19:00 Non-Paraneoplastic Autoimmune Movement Disorders
J. Jankovic, Houston, United States

17:30 – 19:00 **Parkinson-Plus Syndromes** **Room Pollux 2**

Chair: H. Reichmann, Dresden, Germany

Learning Objectives

- To summarize clinical aspects and treatment of multiple system atrophy
- To summarize clinical aspects and treatment of progressive supranuclear palsy
- To summarize clinical aspects and treatment of corticobasal degeneration and corticobasal syndrome

17:30 – 18:00 Multiple System Atrophy
P. Sandroni, Rochester, United States

SCIENTIFIC PROGRAM

TUESDAY
14 November 2017

18:00 – 18:30 Progressive Supranuclear Palsy
A. Fasano, Toronto, Canada

18:30 – 19:00 Corticobasal Degeneration and Corticobasal Syndrome
D. Torres-Russotto, Omaha, United States

In collaboration with evidentia.med

17:30 – 19:00 **Skills Workshop 2: Botulinum Toxin Injections**

Plenary

*Chair: D. Truong, Fountain Valley, United States
T. Tran, Ho Chi Minh City, Vietnam*

Learning Objectives

- To learn injection techniques for the treatment of blepharospasm, hemifacial spasm, and jaw dystonia with botulinum toxin
- To learn injection techniques for the treatment of cervical dystonia with botulinum toxin
- To learn injection techniques for the treatment of limb dystonia and spasticity with botulinum toxin

17:30 – 17:55 Blepharospasm, Hemifacial Spasm and Jaw Dystonia
M. LeDoux, Memphis, United States

17:55 – 18:20 Cervical Dystonia
R. Rosales, Quezon City, Philippines

18:20 – 18:45 Limb Dystonia and Spasticity
R. Rodriguez, Gainesville, United States

18:45 – 19:00 Practical Demonstration


PROGRAM OVERVIEW

WEDNESDAY
15 November 2017

Room	Plenary	Room „Pollux 1“	Room „Pollux 2“	Room „Castor 1“
08:00				
08:30				
09:00		Genetics in Parkinson Disease and Movement Disorders	Other Hyperkinetic Disorders	Pathology of Parkinsonism and Related Disorders
09:30				
10:00	Coffee Break			
10:30	Movement Disorder Developments 2016-2017: Best Articles Published in Parkinsonism and Related Disorders			
11:00				
11:30				
11:45				
12:00	Melvin Yahr Young Investigator Awards			
12:45				
13:00				

 Plenary Sessions

 Timeline Parallel Session

 Point-Counterpoint Interactive Session


 Clinical Practice Session

Wednesday, 15 November 2017


Room „Castor 2“	Room „Castor 3“	Poster Exhibition
Challenging Hyperkinetic Movement Disorders: Spotlight on Ataxia, Chorea and Myoclonus	When It's Not Just Parkinson Disease: Associated Comorbidities and Other Movement Disorders	Oral Poster Session 7

WEDNESDAY
15 November 2017

 Pho Hot Topic Session

 Corporate Session

 Skills Workshop


 Meet the Professor

 Oral Poster Session

 Global Video Session

SCIENTIFIC PROGRAM

WEDNESDAY
15 November 2017

08:30 – 10:00  Pathology of Parkinsonism and Related Disorders **Room Castor 1**

Chair: P. Riederer, Wuerzburg, Germany


Learning Objectives

- To describe alpha synuclein pathology in parkinsonism
- To explain the role of autophagy and the ubiquitin proteasome system in cells and their potential contribution to parkinsonian pathology
- To understand inflammation and other immune mechanisms in parkinsonian pathology

08:30 – 09:00 Unfolding the Mystery of Alpha Synuclein
D. Dickson, Jacksonville, United States

09:00 – 09:30 Breaking Down Autophagy and UPS
Y. J. Oh, Seoul, Republic of Korea

09:30 – 10:00 Immune and Inflammatory Mechanisms in Parkinsonism
R. Kaji, Tokushima, Japan

08:30 – 10:00  Genetics in Parkinson Disease and Movement Disorders **Room Pollux 1**

Chair: Z. Wszolek, Jacksonville, United States

Learning Objectives


- To outline the genes associated with Parkinson and related diseases
- To describe the relationship between genotype and phenotype in parkinsonism
- To describe mitochondrial genetics in Parkinson disease and other movement disorders

08:30 – 09:00 Genetics of Parkinson Disease and Parkinson Disease-Like Genotypes
V. Bonifati, Rotterdam, The Netherlands

09:00 – 09:30 Genetics of Parkinson Disease and Parkinson Disease-Like Phenotypes
R.-M. Wu, Taipei, Taiwan

09:30 – 10:00 Mitochondrial Genetics in Parkinson Disease and Other Movement Disorders
S.-D. Chen, Shanghai, China

In collaboration with evidentia.med

08:30 – 10:00  **Challenging Hyperkinetic Movement Disorders:
Spotlight on Ataxia, Chorea and Myoclonus** **Room
Castor 2**

Chair: J. Bajwa, Riyadh, Saudi Arabia


Learning Objectives

- To recognize the signs of ataxia
- To distinguish choreas associated with different disorders
- To recognize and treat myoclonus

08:30 – 09:00 Simplifying the Complicated World of Ataxia
A. Srivastava, New Delhi, India

09:00 – 09:30 The Colorful Spectrum of Chorea: From Garden Variety to Rare Disorders
J. Roth, Praha, Czech Republic

09:30 – 10:00 Understanding Myoclonus: Presentation, Work Up and Treatment
M. Hallett, Bethesda, United States

08:30 – 10:00  **When It's Not Just Parkinson Disease: Associated
Comorbidities and Other Movement Disorders** **Room
Castor 3**

Chair: I. Bodis-Wollner, Brooklyn, United States


Learning Objectives

- To describe the signs and management of sleep disorders and restless leg syndrome in Parkinson disease
- To explain the overlapping characteristics of essential tremor and Parkinson disease
- To understand the major comorbidities in Parkinson disease

08:30 – 09:00 Sleep Disorders and Restless Legs Syndrome in Parkinson Disease
C. Baumann, Zurich, Switzerland

09:00 – 09:30 The Overlap Between Essential Tremor and Parkinson Disease
A. Fasano, Toronto, Canada

09:30 – 10:00 Comorbidities in Parkinson Disease
C. Tanner, San Francisco, United States

08:30 – 10:00  **Other Hyperkinetic Disorders** **Room
Pollux 2**

Chair: W. Ondo, Houston, United States

Learning Objectives

- To summarize clinical aspects and treatment of myoclonus
- To summarize clinical aspects and treatment of chorea and tics
- To summarize clinical aspects and treatment of cerebellar syndromes

SCIENTIFIC PROGRAM

WEDNESDAY
15 November 2017

- 08:30 – 09:00 Myoclonus
J.M. Rabey, Tel Aviv, Israel
- 09:00 – 09:30 Chorea and Tics
K. Frei, Loma Linda, United States
- 09:30 – 10:00 Cerebellar Syndromes
S. Fujioka, Fukuoka, Japan
- In collaboration with evidentia.med*

OP-7 **Oral Poster Session 7** **Poster Exhibition**
08:30 – 10:00 **Hyperkinetic Movement Disorders**
(4 minutes oral presentation followed by 2 minutes Q&A)



*Chair: P. Sandroni, Rochester, United States
D. Dressler, Hannover, Germany*

- OP-7-02** A clinical cross-sectional study of Huntington's disease patients from China
W. Liu, Chengdu, China
- OP-7-03** Shaky and unsteady: dynamic posturography in essential tremor
S. Prasad, Bangalore, India
- OP-7-04** Ocular motor disorders among X-linked Dystonia Parkinsonism (XDP) patients
M. Macas, Manila, Philippines
- OP-7-05** Cervical dystonia: clinical features of 50 cases in Vietnam
T. Tran, Ho Chi Minh City, Vietnam
- OP-7-06** Evaluation of the relationship between cigarette smoking with risk of essential tremor in Singapore population
F. Setiawan, Singapore, Singapore
- OP-7-07** Differential gene expression analysis reveals pathway based functional association of dysregulated genes in Friedreich's ataxia
H. N. Singh, Delhi, India
- OP-7-08** Efficacy and safety of valbenazine (NBI-98854) in subjects with tardive dyskinesia: results of a long-term study (KINECT 3 extension)
S. Siegert, San Diego, United States
- OP-7-09** Stop signal reaction time in cervical dystonia and Parkinson's patients
A. Roy, Kolkata, India
- OP-7-10** Writer's cramp: brainstem connection revisited
S. Choudhury, Kolkata, India
- OP-7-11** Tremor in spinocerebellar ataxia type12 (SCA-12) mimics essential tremor (ET)
M. K. Narang, New Delhi, India

- OP-7-12 Volumetric magnetic resonance imaging differences in essential tremor compared to Parkinson's disease
G. Franco, Nashville, United States
- OP-7-13 Neuromodulation of NBIA-related dystonia
T. Kmiec, Warszawa, Poland
- OP-7-14 Preliminary evidence of functional compensation in premanifest Huntington's disease using a novel visuospatial working memory task
M. Soloveva, Melbourne, Australia
- OP-7-15 Differences in botulinum toxin treated and non-treated cervical dystonia patients in somatosensory task-related functional imaging response
M. Nevrlý, Olomouc, Czech Republic

10:30 – 11:45

**Movement Disorder Developments 2016 - 2017:
Best Articles Published in *Parkinsonism and Related Disorders***

Plenary

*Chair: V. Bonifati, Rotterdam, The Netherlands
R. Pfeiffer, Portland, United States
Z. Wszolek, Jacksonville, United States*

10:30 – 11:00

Status of *Parkinsonism and Related Disorders*
*R. Pfeiffer, Portland, United States
Z. Wszolek, Jacksonville, United States*

11:00 – 11:45

Best Articles Published in *Parkinsonism and Related Disorders*
*E.-K. Tan, Singapore, Singapore
A. Puschmann, Lund, Sweden*

Best Articles

1. Fabbri M, et al. Do patients with late-stage Parkinson's disease still respond to levodopa? PRD 2016;26:10-16.
2. Ganos C, et al. The clinical syndrome of dystonia with anarthria/aphonia. PRD 2016;24:20-27
3. Nunes MB, et al. Dystonia in Machado-Joseph disease: clinical profile, therapy and anatomical basis. PRD 2015;21:1441-1447.
4. Ding H, et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. PRD 2016;22:68-73.
5. Peretz C, et al. Cancer incidence among Parkinson's disease patients in a 10-yrs time-window around disease onset: a large-scale cohort study. PRD 2016;28:68-72.
6. Moccia M, et al. Caffeine consumption and the 4-year progression of de novo Parkinson's disease. PRD 2016;32:116-119.

WELCOME

WEDNESDAY
15 November 2017

11:45 – 12:45



Melvin Yahr Awards

Plenary

*Chair: D. Truong, Fountain Valley, United States
A. DiRocco, New York, United States*

11:45 – 11:55

3rd place: Maria Díez-Cirarda, Bilbao, Spain
Longitudinal effects of cognitive rehabilitation in Parkinson's disease:
a cognitive, clinical and neuroimaging study

11:55 – 12:05

2nd place: Giulia Franco, Nashville, United States
Volumetric magnetic resonance imaging differences in essential
tremor compared to Parkinson's disease

12:05 – 12:15

1st place: Yimeng Chen, Shanghai, China
MicroRNA-4639 is a regulator of DJ-1 expression and a potential
diagnostic marker for early Parkinson's disease

12:15 – 12:45

IAPRD Award Ceremony



Topic: Basic Neuroscience

- P-001 Purinergic receptor P2Y6 contributes to 1-methyl-4-phenylpyridinium-induced oxidative stress and cell death in neuronal SH-SY5Y cells**
Qian Y.¹, Xu S.¹, Yang X.¹, Xiao Q.¹
¹Ruijin Hospital affiliated to Shanghai JiaoTong University School of Medicine, Neurology, Shanghai, China
- P-002 Bioinformatics analysis of key genes and pathways in cellular model of Parkinson's disease**
Lin D.¹
¹The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Department of Neurology, Guangzhou, China
- P-003 Microarray analysis of an in vitro model induced by an α -synuclein oligomer reveals the expression profile of long non-coding RNA in Parkinson's disease**
Tao E.¹
¹The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Department of Neurology, Guangzhou, China
- P-004 Neuroprotective effect of rutin on iron induced oxidative stress and cytotoxicity in PC12 neuronal cells via Bcl-2/Bax/caspase-3 signaling pathways**
Rahman M.¹
¹SHIATS, Allahabad, U.P., India, Pharmaceutical Sciences, Allahabad, India
- P-005 Cdnf knockout mice show age-dependent changes in the function of dopaminergic terminals**
Panhelainen A.¹, Palm E.¹, Vöikar V.², Lindahl M.¹, Saarma M.¹
¹University of Helsinki, Institute of Biotechnology, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland
- P-006 A dopamine-dependent activity in controlling the motor functions in cadmium induced neurotoxicity: neuroprotective potential of quercetin**
Gupta R.¹, Shukla R.K.¹, Pant A.B.¹, Khanna V.K.¹
¹Developmental Toxicology Division, CSIR- Indian Institute of Toxicology Research, Lucknow, India
- P-007 The therapeutic effect of MANF in the MPTP/MPP⁺-induced model of Parkinson's disease**
Liu Y.¹, Zhang J.¹, Cai Q.¹, Jin L.¹
¹Tongji Hospital of Tongji University, Shanghai, China
- P-008 Discovery of 1,3,5-triazine-thiazoles (DDTR-502) as potent A2A antagonist/MAO-B inhibitor for the treatment of Parkinson's disease**
Singh U.P.¹, Bhat H.R.²
¹Department of Pharmaceutical Sciences, Sam Higginbottom Institute of Agriculture, Technology & Sciences, Allahabad, India, ²Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, India

- P-009** Discovery of novel pyrimidines as adenosine A2A receptor antagonists for benefit in Parkinson's disease
Singh S.¹
¹Department of Pharmaceutical Sciences, Sam Higginbottom Institute of Agriculture, Technology & Sciences, Allahabad, India
- P-010** Rifampicin suppresses inflammation via modulation of autophagy in rotenone-induced microglia
Liang Y.¹, Zhou T.², Lin D.¹
¹Department of Neurology, The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China, ²Department of Emergency, The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
- P-011** Dual neuroprotective role of Hsp2 against α -synuclein aggregates
Jamal M.A.H.M.¹, Islam M.S.¹, Kim H.-J.K.², Hong S.T.¹
¹Department of Biomedical Sciences, Chonbuk National University, Jeonju, South Korea, Jeonju, Republic of Korea, ²JINIS BDRD Institute, Wanju, Republic of Korea
- P-012** The involvement of dopamine in pain modulation in the nucleus accumbens of 6-OHDA induced Parkinson's disease rat model
Zhang X.-Q.¹, Wang F.¹, Lv D.-J.^{1,2}, Li L.-X.^{1,2}, Mao C.-J.², Liu C.-F.^{1,2}
¹Institute of Neuroscience, Soochow University, Suzhou, China, ²Department of Neurology, the Second Affiliated Hospital of Soochow University, Suzhou, China
- P-013** Risk factors of developing Parkinson's disease
Turaeva G.¹, Tursunov D.²
¹New pharm innovation group, Tashkent, Uzbekistan, ²Tashkent Medical Academy, Tashkent, Uzbekistan
- P-015** 17-beta-estradiol: a therapeutic potential drug for Parkinson's disease
Kumar P.¹, Baquer N.¹
¹Jawaharlal Nehru University, School of Life Sciences, New Delhi, India
- P-018** Treadmill training lessens dopaminergic deficiency, enhances BDNF and GDNF biosynthesis, and reduces brain inflammation in the MPTP mouse model of Parkinson's disease
Palasz E.¹, Folcik R.¹, Gasiorowska A.^{1,2}, Niewiadomski W.², Niewiadomska G.¹
¹Neurophysiology, Nencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland, ²Department of Applied Physiology, Mossakowski Medical Research Centre, Warsaw, Poland
- P-019** Rotenone model of Parkinson's syndrome
Kodirova D.¹
¹Tashkent Medical Academy, Medical Biochemistry, Tashkent, Uzbekistan
- P-020** Combination of curcumin and ellagic acid mitigates rotenone induced locomotor, oxidative and mitochondrial deficits in mice
Khatri D.¹, Juvekar A.¹
¹Pharmaceutical Sciences, Institute of Chemical Technology, Mumbai, India
- P-021** Effects of an aerobic exercise on the recovery of forelimb function in 6-OHDA rat-model of Parkinson's disease
Ohno Y.^{1,2}, Horikoshi A.², Imamura K.²
¹Takasaki University of Health and Welfare, Gunma, Japan, ²Maebashi Institute of Technology, Gunma, Japan

- P-022** The importance of apoproteins in the development of Parkinson's disease
Dilzoda A.¹
¹Medical Biochemistry, Tashkent, Uzbekistan
- P-023** Alteration in dopaminergic neurotransmission following exposure to forced swim stress on the neurobehavioral toxicity of lambda-cyhalothrin in rats
Shukla R.K.¹, Gupta R.¹, Pant A.B.¹, Khanna V.K.¹
¹Developmental Toxicology Division, CSIR- Indian Institute of Toxicology Research, Lucknow, India
- P-024** Development of nano-formulation containing rutin for the protective and beneficial effect against 6-hydroxydopamine induced Parkinson's disease model via altered the genetic backgrounds
Sahai V.¹, Kumar V.¹
¹Pharmacy, Sam Higginbottom Institute of Agriculture, Technology and Sciences, Allahabad, India
- P-025** Effect of ropinirole alginate nanocomposite (RANC) on the transgenic *Drosophila melanogaster* model of Parkinson's disease
Naz F.¹, Fatima A.¹, Rahul R.¹, Jyoti S.¹, Hasan Siddique Y.¹
¹Zoology, Aligarh Muslim University, Aligarh, India
- P-026** Evaluation of the therapeutic potential of tangeritin against the symptoms of Parkinson's disease
Fatima A.¹, Naz F.¹, Rahul R.¹, Siddique Y.H.¹
¹Zoology, Aligarh Muslim University, Aligarh, India
- P-027** Molecular mechanisms of neurodegeneration and neuroplasticity in the nigrostriatal system at modeling Parkinson's disease as an instrument for translational medicine
Mingazov E.¹, Khakimova G.¹, Kolacheva A.¹, Kozina E.¹, Medvedev A.², Bazyan A.³, Ugrumov M.¹
¹Laboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, Moscow, Russian Federation, ²Laboratory of Pharmacoproteomics, Institute of Biomedical Chemistry RAS, Moscow, Russian Federation, ³Laboratory of Neurochemical Mechanisms of Learning and Memory, Institute of Higher Nervous Activity and Neurophysiology RAS, Moscow, Russian Federation
- P-028** Novel paradigm for the development of preclinical diagnosis of Parkinson's disease based on searching blood markers and a provocation test
Ugrumov M.¹, Kolacheva A.¹, Kim A.¹, Khakimova G.¹, Nigmatullina R.², Zalyalova Z.², Georgieva S.³, Kudrin V.⁴
¹Laboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, Moscow, Russian Federation, ²Department of the Normal Physiology, Kazan State Medical University, Kazan, Russian Federation, ³Laboratory of Eukaryotic Transcription Factors, Institute of Gene Biology, Moscow, Russian Federation, ⁴Laboratory of Neurochemical Pharmacology, Zakusov Institute of Pharmacology, Moscow, Russian Federation

- P-029 Short-term memory defects and emotional changes following sleep deprivation in a rotenone treated Zebrafish model of Parkinson disease**
Ly D.¹, Zhang X.², Qi D.², Liu C.¹
¹Department of Neurology, the Second Affiliated Hospital of Soochow University, Soochow University, Suzhou, China, ²Institute of Neuroscience, Soochow University, Suzhou, China
- P-030 Recommendation for modeling of parkinsonian syndrome**
Safarbekov D.¹, Tursunov D.²
¹Rehabilitology, Tashkent Medical Academy, Tashkent, Uzbekistan, ²Biochemistry, Tashkent, Uzbekistan
- P-031 Assessment of L-dopa induced dyskinesia**
Tursunov D.¹
¹Biochemistry, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-032 Oxotremorine model of tremor**
Tursunov D.¹
¹Biochemistry, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-033 Correlation analysis between cholinergic system and vegetative status in Parkinson disease**
Azizova R.¹, Shakur M.²
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan, ²Department of Neurology, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan
- P-034 In vivo direct conversion of adult astrocytes to dopaminergic neurons using ALN polycistronic vector**
Kim Y.E.¹, Ma H.-I.¹, Petrova R.², Abeliovich A.²
¹Department of Neurology, Hallym University Sacred Hospital Hallym University, College of Medicine, Anyang, Republic of Korea, ²Pathology and Cell Biology, Columbia University Medical Center, New York, United States
- P-035 Increased free locomotor activity in rats after intraperitoneal injection of 1-methylxanthine versus caffeine: a comparative study**
Jimenez-Botello L.C.¹, Castilla-Cortazar I.², Garcia-Magariño M.², Rios-Perez A.D.³, Avila-Vazquez R.³, Picazo-Picazo O.⁴
¹Escuela de Ciencias de la Salud, Universidad del Valle de Mexico Campus San Luis Potosi, San Luis Potosi, Mexico, ²Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Monterrey, Mexico, ³Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Ciudad de Mexico, Mexico, ⁴Sección de Posgrado e Investigación, Escuela Nacional de Medicina IPN, Ciudad de Mexico, Mexico
- P-036 Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol**
Khan M.M.¹, Xiao J.¹, Patel D.¹, Black C.M.¹, Selley D.E.², LeDoux M.S.¹
¹Neurology, University of Tennessee Health Science Center, Memphis, United States, ²Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, United States
- P-037 Parkinsonian syndrome prevalence in the world**
Akmal I.¹, Azizova D.¹
¹Biochemistry, Tashkent Medical Academy, Tashkent, Uzbekistan

Topic: Behaviour and Cognition

- P-038 Screening of ApoE genotypic frequency and analysis of neurotransmitter levels in Alzheimer's patients of Coimbatore population**
Venugopal A.¹, Venkatesan D.¹, Bharathi G.¹, Vellingiri B.¹
¹Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, India
- P-039 Frailty and cognitive impairment**
Yoon S.J.¹, Kim J.O.¹, Choi S.H.², Park K.-W.³, Jeong J.-H.⁴, Yoon B.⁵
¹Department of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Republic of Korea, ²Department of Neurology, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea, ³Department of Neurology, Aong-A Medical Center, Dong-A University College of Medicine, Busan, Republic of Korea, ⁴Department of Neurology, Ewah Medical Center Mokdong Hospital, Seoul, Republic of Korea, ⁵Department of Neurology, Konyang University Hospital, College of Medicine, Konyang University, Daejeon, Republic of Korea
- P-040 Influence of physical training on executive functions in Parkinson's disease**
Slotwinski K.¹, Marusiak J.², Budrewicz S.¹, Koszewicz M.¹, Podemski R.¹
¹Neurology, Wrocław Medical University, Wrocław, Poland, ²Kinesiology, Academy of Physical Education in Wrocław, Wrocław, Poland
- P-041 Clinical features associated with cognitive impairment in Chinese Parkinson's disease patients: a cross-sectional study**
Du J.¹, Cui S.¹, Chen S.¹
¹Department of Neurology, Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
- P-042 Rho kinase inhibitors – a growing neuroprotective therapeutic paradigm**
Abbi V.¹, Piplani P.¹
¹University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
- P-043 Cognitive impairment in Parkinson's disease**
Narkulova K.¹, Abdullaev B.², Kostyunina A.¹
¹Neurology, Tashkent Pediatrics Medical Institute, Tashkent, Uzbekistan, ²Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-044 Neuropsychiatric disorders in idiopathic Parkinson's disease**
Halder S.¹, Kulsum M.U.², Mondal B.², Dutt A.¹, Anand S.S.², Kumar H.²
¹Institute of Neurosciences Kolkata, Neurology, Kolkata, India, ²Neurology, Institute of Neurosciences Kolkata, Kolkata, India
- P-045 Antidepressants efficiency in patients with depression and depression related to Parkinson's disease**
Kostyunina A.¹, Abdullaev B.², Narkulova K.¹
¹Neurology, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan, ²Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-046 Psychotherapeutic treatment of cognitive impairment in children with tic hyperkinesia**
Sattarova D.¹, Madjidova Y.², Azimova N.², Achilova K.²
¹Folk Medicine, Rehabilitation and Physical Development, Tashkent Medical Academy, Tashkent, Uzbekistan, ²Neurology, Child Neurology and Medical Genetics, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan

- P-047 Neuropsychiatric symptoms impact on quality life of patients with Parkinson's disease**
Sultonova D.¹, Akbarkhodjaeva Z.¹
¹Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-048 Characteristics of cognitive disturbances in early stages of Parkinson disease**
Ruzimova N.¹, Azizova R.¹
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-049 A comparison of cognition and toe tapping speed regulation ability in Parkinson's disease patients: a pilot study**
Taniguchi S.¹, Peper F.¹, Shimokawa T.¹
¹Department of Health Sciences, Kobe University, Kobe, Japan
- P-050 Visuospatial dysfunction in cube copying test and clock drawing test in non-demented Parkinson's disease: a volumetric analysis**
Ahn T.-B.^{1,2}, Na B.S.², Lee D.²
¹Department of Neurology, Kyung Hee University, Seoul, Republic of Korea, ²Department of Neurology, College of Medicine, Kyung Hee University, Seoul, Republic of Korea
- P-051 The effect of apolipoprotein E ϵ 4 (APOE ϵ 4) on visuospatial working memory in healthy elders and amnesic mild cognitive impairment patients: an event-related potentials study**
Gu L.¹, Zhang Z.¹, Chen J.¹, Gao L.¹, Shu H.¹, Wang Z.¹, Liu D.¹, Yan Y.², Li S.³
¹Department of Neurology, Affiliated ZhongDa Hospital, Medical School, Southeast University, Nanjing, China, ²Department of Psychology, Xinxiang Medical University, Xinxiang, China, ³Department of Biophysics, Medical College of Wisconsin, Milwaukee, United States
- P-052 The impact of apolipoprotein E gene polymorphism on the cerebral blood flow in patients with mild cognitive impairment**
Zhu L.¹, Liao W.X.¹, Zhang Z.¹, Wang Z.¹, Chen J.¹, Shu H.¹, Bai F.¹
¹Department of Neurology, Affiliated ZhongDa Hospital Medical School, Southeast University, Nanjing, China
- P-053 Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of galantamine to treat Alzheimer's disease**
Jain S.¹, Jain R.¹
¹Pharmacy, Bhagyoday Tirth Pharmacy College, Sagar, India
- P-054 C9ORF72 and frontotemporal dementia: a systematic review and meta-analysis**
Zhou Q.¹, Qu Q.¹
¹Department of Neurology, First Affiliated Hospital of Xi'an, Jiao Tong University, Xi'an, China

Topic: Hyperkinetic Movement Disorders

- P-055** Some movement disorders as diagnostic predictions of juvenile chorea
Sanoyeva M.¹
¹Bukhara State Medical Institute, Neurology, Bukhara, Uzbekistan
- P-056** Co-segregating CACNA1A indel in pedigree with blepharospasm
Tian J.¹, Valente E.M.², Defazio G.³, Petrucci S.⁴, Gigante A.F.³, Vemula S.R.¹, Xiao J.¹, LeDoux M.S.¹
¹Neurology, University of Tennessee Health Science Center, Memphis, United States, ²Molecular Medicine, University of Pavia, Pavia, Italy, ³Basic Clinical Sciences, Neuroscience and Sense Organs, Aldo Moro University of Bari, Bari, Italy, ⁴Neurological Sciences, Sapienza University, Rome, Italy
- P-057** Excellent outcome after bilateral pallidal deep brain stimulation in generalized dystonia due to amphetamine-induced bilateral basal ganglia necrosis
Suengtaworn A.¹, Pitakpatapee Y.¹, Srivanitchapoom P.¹
¹Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
- P-058** Identification imprinting gene expression at 15q11-q13 region in Angelman syndrome
Vijayakumar P.¹
¹Dept. of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, India
- P-059** When movement disorders hurt: addressing pain in hyperkinetic disorders
Relja M.¹, Miletic V.¹
¹Department Neurology, Medical School University of Zagreb, Zagreb, Croatia
- P-060** Case report: chorea gravidarum persisting after delivery
Kamen C.¹, Frei K.¹
¹Neurology, Loma Linda University, Loma Linda, United States
- P-061** The first case report of neuroacanthocytosis in Vietnam
Vo Nguyen Ngoc T.¹, Nguyen Huu C.²
¹Neurology, International Neurosurgery Hospital, Ho Chi Minh, Vietnam, ²Neurology, Pham Ngoc Thach University of Medicine, Ho Chi Minh, Vietnam
- P-062** The role of botulinum toxin on pain and gait impairment in cervical dystonia
Chatterjee K.¹, Choudhury S.¹, Roy A.¹, Mondal B.¹, Kumar H.²
¹Neurology, Institute of Neurosciences Kolkata, Kolkata, India, ²Neurocrine Biosciences, Inc., Institute of Neurosciences Kolkata, Kolkata, India
- P-063** Start react paradigm in patients with cervical dystonia
Singh R.¹, Choudhury S.², Roy A.², Chatterjee K.², Mondal B.², Baker M.³, Baker S.⁴, Kumar H.²
¹Neurology, Institute of Neurology, Kolkata, India, ²Neurology, Institute of Neurosciences Kolkata, Kolkata, India, ³Neurology, Institute of Neurosciences, Newcastle University, Newcastle Upon Tyne, United Kingdom, ⁴Movement Neuroscience, Institute Of Neuroscience, Newcastle University, Newcastle Upon Tyne, United Kingdom

- P-064 Hemidystonia in a 28-year old CLCN2 homozygous Filipino female**
Torres J.A.K.¹, Rosales R.¹
¹University of Santo Tomas Hospital, Neurology and Psychiatry, Manila, Philippines
- P-065 A Chinese rapid-onset dystonia-parkinsonism case and literature review**
Yang L.¹, Zhao B.¹, Hou Y.¹, Chen Y.¹, Cao B.¹, Shang H.¹
¹Neurology, West China Hospital, Sichuan University, Chengdu, China
- P-066 Depression and bladder dysfunction in patients with Huntington's disease**
Kolenc M.¹, Kobal J.², Simon P.²
¹Neurology Division, Novo Mesto General Hospital, Novo mesto, Slovenia, ²Neurology, UMC Ljubljana, Ljubljana, Slovenia
- P-067 Localization of dystonic muscles with positron emission tomography/computed tomography for the treatment of cervical dystonia**
Shen Y.¹, Hu Y.¹, Cai L.², Li B.¹, Pan L.¹, Jin L.¹
¹Department of Neurology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China, ²Department of Scientific Research, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
- P-068 Current clinical views on Wilson's disease**
Wang X.-P.¹
¹Department of Neurology, Shanghai Tong-Ren Hospital, Shanghai Jiao-Tong University, Shanghai, China
- P-069 Deep brain stimulation: a more promising treatment indication in Parkinson's disease dementia and Parkinson's disease plus Alzheimer's disease?**
Wang X.-P.¹
¹Department of Neurology, TongRen Hospital Shanghai JiaoTong University School of Medicine, Shanghai, China
- P-070 Bilateral globus pallidus internus deep brain stimulation for dystonic opisthotonus in atypical pantothenate kinase-associated neurodegeneration syndrome**
Mohd Fauzi N.A.¹, Norlinah M.I.², Jegan T.³, Siti Hajar M.D.², Zariah A.A.⁴, Azlina A.A.⁵, Teh P.C.⁶
¹Department of Medicine, Faculty of Medicine, University Technology MARA (UiTM), Sungai Buloh, Malaysia, ²Department of Medicine, Pusat Perubatan University Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ³Department of Neurosurgery, Pusat Perubatan University Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ⁴Department of Medicine, Hospital Sultanah Nur Zahirah, Kuala Terengganu, Malaysia, ⁵Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, ⁶Department of Neurology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

Topic: Other Movement Disorders

- P-071 Actin polymerization dynamics are affected in spinocerebellar ataxia type 6**
Liu J.¹, Yang Y.², Mei F.³, Hu J.³, Meng X.³, Wang L.², Yin Y.³, Wang L.⁴
¹Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China, ²Department of Neurology, Section I, Dali Bai Autonomous Prefecture People's Hospital, Dali, China, ³School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China, ⁴Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing, China
- P-072 A curious case of restless legs syndrome masquerading as akathisia**
Tan S.M.¹
¹Department of Psychiatry, Singapore General Hospital, Singapore, Singapore
- P-073 Primary progressive freezing gait with bilateral basal ganglia lesion in a uremic patient**
Kim S.J.¹
¹Department of Neurology, Busan Paik Hospital, Inje University, Busan, Republic of Korea
- P-074 Facio-oculo-palatal myoclonus complicated by recurrent brainstem infarction**
Pitakpatapee Y.¹, Srikajon J.¹, Rattanathamsakul N.¹, Suengtaworn A.¹, Srivanitchapoom P.¹
¹Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
- P-076 Paradoxical worsening of parkinsonism upon neuroleptic withdrawal: more common than we think?**
Florescu A.¹, Whitney D.¹, Bhatti D.¹, Bertoni J.¹, Torres-Russotto D.¹
¹Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, United States
- P-077 Biochemical profile in patients with neurological Wilson's disease**
Kumar N.¹, Joshi D.²
¹Neurology, Indira Gandhi Institute of Medical Sciences, Patna, India, ²Neurology, Institute of Medical Sciences, Varanasi, India
- P-078 The pathogenesis of vascular parkinsonism**
Makhkamova M.¹
¹Neuroscience, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-079 Parkinsonism in manganese-exposed welder: case report**
Gultekin M.¹
¹Department of Neurology, Erciyes University School of Medicine, Kayseri, Turkey
- P-080 The clinical features of stroke related restless legs syndrome**
Zhang X.J.¹, Zhu X.Y.¹, Liu Y.¹, Wu Y.C.¹
¹Department of Neurology, Shanghai General Hospital, Shanghai, China
- P-081 CSF amyloid- β 40 and 42 are decreased in amyloid PET (-) normal pressure hydrocephalus**
Lim T.S.¹, Kim H.J.¹, Moon S.Y.¹
¹Ajou University School of Medicine, Department of Neurology, Suwon, Republic of Korea

- P-082** Hormonal pathogenetic effects and vascular-immunological aspects in secondary vascular parkinsonism
Akramova D.¹, Rakhimbaeva G.¹
¹Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-083** Twofold load of tandem repeat expansion and their impact on ADCA patients
Shakya S.¹, Srivastava A.K.¹, Faruq M.², Kumar D.²
¹Department of Neurology, All India Institute of Medical Sciences, New Delhi, India, ²CSIR-IGIB, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
- P-084** Modifiers of age at onset in spinocerebellar ataxia type 2(SCA2): CAG length of other SCA loci do not influence age at onset in SCA2
Singh R.¹, Sonakar A.K.², Srivastava A.K.², Faruq M.³
¹Neurology, All India Institute of Medical Sciences New Delhi, delhi, India, ²Neuroscience Centre, All India Institute of Medical Sciences, New Delhi, India, ³CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
- P-085** New insight in the screening of tandem repeats among spinocerebellar ataxia patients
Suroliya V.¹, Srivastava A.K.¹, Faruq M.²
¹Neurology, AIIMS, Delhi, India, ²Molecular Medicine, CSIR-IGIB, Delhi, India
- P-086** Interrelation of cognitive impairments and quality of life between motor disorders in patients with vascular parkinsonism
Tolibov D.¹, Roziqova M.¹
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-087** Features of cognitive functions of Parkinson's disease (PD) and vascular parkinsonism
Tolibov D.¹, Rakhimbaeva G.²
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan, ²Department of Neurology, Faculty of Health Science, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-088** Features of MRI signs of Parkinson's disease (PD) and vascular parkinsonism
Umarov A.¹, Rakhimbaeva G.¹
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-089** Two new mutations of CP gene associated with aceruloplasminemia and basal ganglia cavitation
Riboldi G.M.¹, Anstett K.², Lau H.², Swope D.¹
¹Fresco Institute for Parkinson's and Movement Disorders, NYU Langone Medical Center, New York, United States, ²Division of Neurogenetics, NYU Langone Medical Center, New York, United States
- P-090** Conflicts of western and eastern publications regarding spinocerebellar ataxias
Turgunkhujaev O.¹, Tolibova N.¹
¹Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan

Topic: Parkinson 1

- P-091 Parkinson's disease among combat veterans exposed to hazardous chemicals**
*Siddharthan K.*¹
¹Research, James A Haley Veterans Hospital, Tampa, United States
- P-092 Dietary habits in Parkinson's disease: adherence to Mediterranean diet**
*Cassani E.*¹, *Barichella M.*¹, *Ferri V.*¹, *Pinelli G.*¹, *Iorio L.*¹, *Bolliri C.*¹, *Caronni S.*¹, *Fairman S.*¹, *Mottolese A.*¹, *Pusani C.*¹, *Monajemi F.*¹, *Lubisco A.*², *Pasqua M.*¹, *Cereda E.*³, *Frazzitta G.*⁴, *Petroni M.L.*⁵, *Pezzoli G.*¹
¹ASST G. Pini-CTO, ex-ICP, Parkinson Institute, Milano, Italy, ²Department of Statistical Sciences "P. Fortunati", University of Bologna, Bologna, Italy, ³Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴Department of Brain Injury and Parkinson Disease, Rehabilitation "Moriggia-Pelascini" Hospital Gravedona ed Uniti, Como, Italy, ⁵Department of Functional Rehabilitation, "Sol et Salus" Hospital, Torre Pedrera, Rimini, Italy
- P-093 Can EMG help elucidate other possible cause of gait impairment in PD?**
*Alvarez M.*¹
¹Neurology Associates of San Antonio, San Antonio, United States
- P-094 Assessment of the severity and progression of Parkinson's disease**
*Kim Y.*¹, *Kamenova S.*¹
¹Neurology and Neurosurgery, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
- P-095 Carrier mediated delivery system bearing dopamine for effective management of Parkinsonism**
*Bhargava M.*¹, *Bhargava S.*²
¹ICFAI University, Kanpur, India, ²Himalayan University, Kanpur, India
- P-096 Could autophagy-related proteins be a biomarker in early Parkinson's disease? Potential novel CSF biomarkers in Parkinson's disease**
*Jang W.*¹, *Youn J.*²
¹Gangneung Asan Hospital, University of Ulsan, Neurology, Gangneung, Republic of Korea, ²Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- P-097 Predictors of further freezing of gait in Parkinson's disease: a prospective study from southwest of China**
*Qu R.*¹, *Wei Q.*¹, *Cao B.*¹, *Song W.*¹, *Hou Y.*¹, *Liu H.*¹, *Yuan X.*¹, *Zhao B.*¹, *Wu Y.*¹, *Shang H.*¹
¹Neurology, West China Hospital, Sichuan University, Chengdu, China
- P-098 Broad impairments of executive functions in Parkinson's patients: a meta-analysis**
*Chan J.*¹, *Deng K.F.*¹, *Wu J.M.*¹, *Liang D.X.*¹, *Yan J.H.*¹
¹Neuroscience, Shenzhen, China
- P-099 Ancient Chinese description of Parkinson's disease**
Le W.^{1,2}, *Li S.*¹
¹Center for Clinical Research on Neurological Diseases, 1st Hospital of Dalian Medical University, Dalian, China, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Neurology, Shanghai, China

- P-100** microRNAs in plasma as biomarkers for Parkinson's disease
Le W.^{1,2}, Yang Z.¹, Li T.¹, Li S.¹
¹Center for Clinical Research on Neurological Diseases, Dalian, China, ²Institute of Neurology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China
- P-101** Nurr1 deficiency-mediated inflammatory injury to nigral dopamine neurons in Parkinson's disease
Dong L.¹, Wang Y.¹, Liu X.Y.¹, Le W.D.¹
¹Center for Translational Research on Neurological Disease, 1st Affiliated Hospital, Dalian Medical University, Dalian, China
- P-102** Diabetes mellitus accelerates the onset of levodopa-related motor complications and leads to lower MoCA scores in patients with mild to moderate Parkinson's disease
Mohamed Ibrahim N.¹, Ramli R.², Shah S.A.³
¹Department of Medicine, Faculty of Medicine, UKM, Bandar Tun Razak, Malaysia, ²Department of Medicine, Faculty of Medicine, UKM, Kuala Lumpur, Malaysia, ³Department of Community Health, Faculty of Medicine, UKM, Kuala Lumpur, Malaysia
- P-103** Patterns of neuropsychological profiles according to severity of depressive symptoms in newly diagnosed Parkinson's disease patients
Kim S.J.¹
¹Department of Neurology, Busan Paik Hospital, Inje University, Busan, Republic of Korea
- P-104** Investigation of LRRK2 variant and essential tremor
Ratnagopal P.¹, Kumar P.M.¹, Tan E.K.¹
¹Neurology, National Neuroscience Institute, Singapore, Singapore
- P-105** Mutational analysis of Parkin gene in early-onset of Parkinson's disease of Coimbatore population
Venkatesan D.¹, Vellingiri B.¹, Balasubramanian V.¹, Ramkumar S.², Manickam S.³, Bharathi G.¹
¹Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, India, ²Medicine, Karpagam Faculty of Medical Sciences and Research, Coimbatore, India, ³Zoology, Vellalar College for Women, Erode, India
- P-106** White matter hyperintensity and dementia conversion in Parkinson's disease
Cheon S.-M.¹, Kim J.W.¹
¹Neurology, Dong-A University School of Medicine, Busan, Republic of Korea
- P-107** Multi-center observational study of personality and impulse control disorders in Japanese patients with Parkinson's disease
Shinoda T.¹, Nakashita S.², Hamada M.³, Hirono K.⁴, Ito M.⁴, Kashihara K.⁵, Miyagi T.⁶, Namihira Y.⁶, Tokashiki T.⁷, Nakashima K.⁸, Maeda T.^{9,10}
¹Neurology, Research Institute for Brain and Blood Vessels-Akita, Akita, Japan, ²Neurology, Tottori Prefectural Kousei Hospital, Kurayoshi, Japan, ³Division of Neurology- Department of Brain and Neurosciences- Faculty of Medicine, Tottori University, Yonago, Japan, ⁴Division of Rehabilitation, Okayama Kyokuto Hospital, Okayama, Japan, ⁵Neurology, Okayama Kyokuto Hospital, Okayama, Japan, ⁶Cardiovascular Medicine, Nephrology and Neurology, Graduate School of Medicine, University of the Ryukyus, Nishiaru, Japan, ⁷Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan, ⁸Neurology, National Hospital Organization Matsue Medical Center, Matsue, Japan, ⁹Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan, ¹⁰Department of Neurology, Research Institute for Brain and Blood Vessels-Akita, Akita, Japan

- P-108 ABCG2 variant rs2231142 in Parkinson's disease**
Mai P.-T.¹, To T.B.-P.², Le D.-T.³, Tran N.-T.⁴, Le M.⁴, Do D.-M.³
¹Physiology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam, ²Neurology, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam, ³Center for Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam, ⁴Movement Disorder Unit, Neurology Department, University of Medicine and Pharmacy at Ho Chi Minh City, University Medical Center, Ho Chi Minh, Vietnam
- P-109 Quality of life in patients with Parkinson's disease**
Kamenova S.¹, Kuzhibayeva K.¹, Kondybayeva A.¹, Akanova A.¹
¹Neurology and Neurosurgery, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
- P-110 Heat shock Drosophila serine protease-2 mediated detoxification of α-synuclein induced neurotoxicity in a Drosophila model of Parkinson's disease**
Islam M.S.¹, Hong S.T.¹
¹Medical Science, Chonbuk National University Medical School, Jeonju, Republic of Korea
- P-111 Characteristics of neurocognitive disorders in patients with Parkinson's disease in Vietnam**
Ny T.T.H.¹, Thang T.C.², Tai T.N.³, Minh L.³
¹Neurology Department, Thong Nhat Hospital, Ho Chi Minh City, Vietnam, ²Neurology Department, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam, ³Neurology Department, University Medical Center, Ho Chi Minh City, Vietnam
- P-112 Excessive daytime sleepiness decreases the quality of life and daytime activity in Parkinson's disease**
Babkina O.¹, Poluektov M.², Levin O.¹
¹Neurology Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation, ²Neurology Department, Sechenov First Moscow State Medical University, Moscow, Russian Federation
- P-113 The impact of levodopa-induced complications on the quality of life of patients with Parkinson's disease**
Manharlal P.K.¹, Lim E.-C.², Tan E.-K.²
¹National Neuroscience Institute, Neurology, Singapore, Singapore, ²Neurology, Singapore, Singapore
- P-114 Screening for TMEM230 mutations in young onset Parkinson's disease**
Ma D.¹, Ng S.H.², Setiawan F.², Foo J.N.^{3,4}, Ng E.Y.², Zhao Y.⁵, Liu J.-J.⁴, Tan E.K.^{1,2,6}
¹Department of Neurology, Singapore General Hospital, Singapore, Singapore, ²National Neuroscience Institute, Singapore, Singapore, ³Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore, ⁴Human Genetics, Genome Institute of Singapore, A*STAR, Singapore, Singapore, ⁵Department of Clinical Research, Singapore General Hospital, Singapore, Singapore, ⁶Neuroscience & Behavioural Disorders, Duke-NUS Medical School, Singapore, Singapore
- P-115 Levodopa-induced motor complications in Vietnamese patients with Parkinson's disease**
Dang T.H.T.¹, Tran N.T.¹, Le M.¹
¹Neurology, University Medical Center of Ho Chi Minh City, Ho Chi Minh City, Vietnam

- P-116 Effect of white matter hyperintensities on non-motor symptoms in Parkinson's disease**
Kim J.S.¹, Cho J.W.¹, Youn J.¹, Park J.K.², Jeong H.³, Na B.¹
¹Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Neurology, Soonchunhyang University, Gumi, Republic of Korea, ³Neurology, Kyungsang University Hospital, Changwon, Republic of Korea
- P-117 Prevalence of Axis-1 DSM-4 psychiatric disorders in patients with parkinsonism using a structured interview(MINI) in a rural-based neurology clinic in India**
Singh S.¹, Desai S.², Desai D.¹, Pandya H.¹
¹Medicine, PramukhSwami Medical College, Anand, India, ²Neurology, Pramukhswami Medical College, Karamsad, Anand, India
- P-118 Cognitive impairment in patients with Parkinson's disease**
Manatova R.¹, Kamenova S.¹
¹Neurology and Neurosurgery, Afsendiyarov Kazakh National Medical University, Almaty, Kazakhstan
- P-119 Prevalence of Parkinson's disease in Bihar, India**
Kumar G.¹
¹Neurology, All India Institute of Medical Sciences Patna, Patna, India
- P-120 Study of the role of vitamin D and insulin resistance in patients with Parkinson's disease**
Bajenaru O.-L.¹, Ene A.², Ribigan A.², Terecoasa E.³, Tiu C.³, Bajenaru O.-A.³
¹Gerontology and Geriatrics, "Ana Aslan" National Institute of Gerontology and Geriatrics from the University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania, ²Neurology, University Emergency Hospital Bucharest, Bucharest, Romania, ³Neurology, University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania
- P-121 Association of SNCA in late-onset Parkinson's disease with 22q11.2 deletion**
Vellingiri B.¹, Venkatesan D.¹, Bharathi G.¹, Ramkumar S.², Manickam S.³, Balasu-bramanian V.¹
¹Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, India, ²Medicine, Karpagam Faculty of Medical Sciences and Research, Coimbatore, India, ³Zoology, Vellalar College for Women, Erode, India
- P-122 Peripheral distribution of α -synuclein pathology: a case of Parkinson's disease**
Jang M.¹, Kim A.¹, Kim H.-J.¹, Park S.-H.², Jeon B.¹
¹Neurology, Seoul National University Hospital, Seoul, Republic of Korea, ²Pathology, Seoul National University Hospital, Seoul, Republic of Korea
- P-123 Depression in Parkinson's disease: an initial study with the Beck Depression Inventory**
Nguyenthanh B.¹
¹Neurology Department, Hanoi Medical University, Hanoi, Vietnam
- P-124 Occipital hypometabolism on [18F]-FDG PET scans in patients with idiopathic REM sleep behavior disorder is less prominent than those of patients with Parkinson's disease**
Kashihara K.¹, Ban M.², Baba T.³, Takeda A.⁴
¹Neurology, Okayama Kyokuto Hospital, Okayama, Japan, ²Radiology, Okayama Kyokuto Hospital, Okayama, Japan, ³Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁴Neurology, Sendai Nishitaga Hospital, Sendai, Japan

- P-125 Identification of a novel locus in a large pedigree with Parkinson's disease**
Monfrini E.¹, Malaguti M.C.², Ottaviani D.³, Di Giacomo R.⁴, Straniero L.⁵, Duga S.^{5,6}, Di Fonzo A.⁷
¹Department of Pathophysiology and Transplantation, University of Milan, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Neuroscience Section, Milano, Italy, ²Neurology Department, Santa Chiara Hospital, Trento, Italy, ³U.O di Neurologia dell'Ospedale S. Maria del Carmine, Rovereto, Italy, ⁴Center for Neurocognitive Rehabilitation (CERiN), Mind/Brain Sciences (CIMEC), University of Trento, Trento, Italy, ⁵Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ⁶Humanitas Clinical and Research Center, Rozzano, Italy, ⁷IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Milano, Italy
- P-126 Clinical characteristics of young onset Parkinson's disease**
Thai H.¹, Le Van T.², Le M.³, Tran Ngoc T.¹
¹Neurology, University Medical Center, Ho Chi Minh City, Vietnam, ²Neurology, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam, ³Neurology, University Medical Center, Ho Chi Minh City, Vietnam
- P-127 The usefulness of skin fold thickness measurements in the estimation of the nutritional status in Parkinson disease**
Budrewicz S.¹, Koszewicz M.¹, Zmarzly A.², Raczka D.², Koziorowska - Gawron E.¹, Szczeptańska A.¹, Slotwinski K.¹, Podemski R.¹
¹Neurology, Wrocław Medical University, Wrocław, Poland, ²Clinical Nutrition Unit, Gromkowski Hospital, Wrocław, Poland
- P-128 Do hypertension and calcium channel blocker agents increase the risk of Parkinson disease?**
Sanyasi R.D.L.R.^{1,2}, Pinzon R.^{3,4}
¹Neurology Department, Duta Wacana Christian University, Yogyakarta, Indonesia, ²Emergency Department, Dr. Efram Harsana Air Force Hospital, Magetan, Indonesia, ³Neurology Department, Bethesda Hospital, Yogyakarta, Indonesia, ⁴Neurology Department, Medical Faculty Duta Wacana Christian University, Yogyakarta, Indonesia
- P-129 Sleep disturbances and quality of life in people with Parkinson's disease**
Chotphoksap U.¹, Tan D.², Tan S.B.¹, Tan E.K.³, Wang S.¹, Chew J.S.¹, Poh E.¹, Chen X.³, Kam T.Y.¹, Prakash K.M.³
¹Department of Nursing, Singapore General Hospital, Singapore, Singapore, ²Department of Physiotherapy, Singapore, Singapore, ³Department of Neurology, National Neuroscience Institute (SGH campus), Singapore, Singapore
- P-130 Validity and reliability study of Indonesian version of scales for outcomes in Parkinson's Disease-Sleep (SCOPA-SLEEP INA)**
Astiny D.¹, Dewati E.¹, Octaviana F.¹, Prihartono J.²
¹Neurology, University of Indonesia, Jakarta, Indonesia, ²Community Medicine, University of Indonesia, Jakarta, Indonesia
- P-131 Glucocerebrosidase gene variants in Malays with Parkinson's disease**
Mohamad Pakarul Razy N.E.¹, Abdul Murad N.A.¹, Syafuruddin S.E.¹, Ahmad Annuar A.², Lim S.-Y.³, Jamal R.¹, Mohamed Ibrahim N.⁴
¹UKM Medical Molecular Biology Institute (UMBI), Cheras, Malaysia, ²Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, ³Division of Neurology and the Mah Pooi Soo & Tan Chin Nam Centre for Parkinson's & Related Disorders, University of Malaya, Kuala Lumpur, Malaysia, ⁴Department of Medicine, Chancellor Tuanku Muhriz Hospital & UKM Medical Centre (UKMMC), Cheras, Malaysia

- P-132 Evaluation of serum hepcidin concentrations in Parkinson's disease patients**
Manolov V.¹, Hadjidekova S.², Victor M.³, Vasilev V.⁴, Petrova M.³, Kunchev T.³, Jelev Y.³, Jeliazkov P.³, Gramatikova Z.⁵, Voleva S.⁶, Tzatchev K.¹, Traykov L.³
¹Dept. of Clinical Laboratory and Clinical Immunology, Medical University, Sofia, Bulgaria, ²Dept. of Medical Genetics, Sofia, Bulgaria, ³Dept. of Neurology, Medical University, Sofia, Bulgaria, ⁴Clinical Laboratory and Clinical Pharmacology, Sofia, Bulgaria, ⁵R.E.D. Laboratories, Zellik, Belgium, ⁶Dept. of Medical Genetics Virology, NCIPD, Sofia, Bulgaria
- P-133 A nationwide epidemiologic study of Parkinson's disease in Korea using national health insurance database**
Lee W.-W.¹, Jeon B.^{2,3}, Kim H.-J.^{2,3}, Lee J.⁴, Kim A.³, Jang M.-H.³
¹Department of Neurology, Nowon Eulji Medical Center, Eulji University, Seoul, Republic of Korea, ²Department of Neurology, Seoul National University College of Medicine, Seoul, Republic of Korea, ³Movement Disorder Center, Seoul National University Hospital, Seoul, Republic of Korea, ⁴Division of Clinical Epidemiology, Biomedical Research Institution, Seoul National University Hospital, Seoul, Republic of Korea
- P-134 Evaluation of serum amino acid levels in patients with Parkinson's Disease**
Figura M.¹, Kuśmierska K.², Bucior E.³, Szluifik S.¹, Koziorowski D.¹, Jamrozik Z.⁴, Janik P.⁴
¹Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland, ²Screening Department, Institute of Mother and Child, Warsaw, Poland, ³Medical University of Warsaw, Warsaw, Poland, ⁴Department of Neurology, Medical University of Warsaw, Warsaw, Poland
- P-135 Resting-state network connectivity in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson's disease**
Hou Y.¹, Yang J.¹, Luo C.¹, Ou R.¹, Song W.¹, Gong Q.², Shang H.¹
¹Neurology, West China Hospital, Sichuan University, Chengdu, China, ²Radiology, Huaxi MR Research Center, West China Hospital, Sichuan University, Chengdu, China
- P-136 Could cardiac sympathetic denervation predict levodopa-induced dyskinesia in de novo Parkinson's disease?**
Kang S.-J.¹, Ahn J.Y.², Kim H.-T.³
¹Neurology, H+ Yangji Hospital, Seoul, Republic of Korea, ²Neurology, Seoul Medical Center, Seoul, Republic of Korea, ³Neurology, College of Medicine, Hanyang University, Seoul, Republic of Korea
- P-137 Resting-state fMRI study on drug-naïve Parkinson's disease patients with hyposmia**
Shushan Z.¹, Shan P.¹, Wei Z.¹, Yirong W.¹, Juming Y.¹
¹Neurology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
- P-138 Falls in patients with Parkinson's disease (PD) and their association with bone mineral density (BMD)**
Khoo C.S.¹, Shahrudin M.¹, Mohamed Ibrahim N.¹, Wan Zaidi W.A.¹, Ng C.F.¹, Teh P.C.², Mohd Fauzi N.A.³, Remli R.¹, Wan Yahya W.N.N.¹, Tan H.J.¹
¹Department of Medicine, University Kebangsaan Malaysia Medical Centre, Cheras, Malaysia, ²Department of Neurology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, ³Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Malaysia

- P-139** A selective role of striatal dopamine in the timing of anticipatory postural adjustments at gait initiation in patients with Parkinson's disease
Palmisano C.^{1,2}, Brandt G.¹, Pozzi N.G.¹, Brumberg J.³, Leporini A.¹, Marotta G.⁴, Cavallari P.⁵, Frigo C.A.², Pezzoli G.⁶, Isaias I.U.^{1,6}
¹Neurology, University Hospital and JMU Wuerzburg, Wuerzburg, Germany, ²DEIB, Politecnico di Milano, Milano, Italy, ³Neuroimaging, University Hospital and JMU Wuerzburg, Wuerzburg, Germany, ⁴Neuroimaging, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy, ⁵Physiology, Università degli Studi di Milano, Milano, Italy, ⁶Neurology, ASST Gaetano Pini-CTO, Milano, Italy
- P-140** Betaband event-related desynchronization prior to simple lower limb movement and simulated gait initiation in Parkinson's disease patient: magnetoencephalography study
Yun J.Y.¹, Jeon B.²
¹Department of Neurology, Ewha Womans University School of Medicine, Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea, ²Department of Neurology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- P-141** Taking the step towards predicting Parkinson's disease
Chimagomedova A.¹, Levin O.¹, Batukaeva L.¹
¹Centre of Extrapyramidal Disorders, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation
- P-142** Rapid eye movement sleep behavior disorder and predominant non-motor symptoms subtypes in Chinese Parkinson's disease patients: a questionnaire-based study
Wu Y.¹, Ou R.¹, Liu H.¹, Wei Q.¹, Zhang L.¹, Cao B.¹, Song W.¹, Yang J.¹, Zhao B.¹, Shang H.¹
¹Neurology, West China Hospital, Sichuan University, Chengdu, China
- P-143** Motor and cognitive impairment in patients with Parkinson's disease who underwent ischemic stroke
Mukhamedkhanova M.¹, Madjidova Y.¹, Khanova M.¹
¹Neurology, Child Neurology and Medical Genetics, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan
- P-144** Relationship between predominant non-motor subtypes and motor fluctuations in Parkinson's disease: a cohort study from southwest of China
Wu Y.¹, Wei Q.¹, Ou R.¹, Liu H.¹, Cao B.¹, Zhang L.¹, Yuan X.¹, Yang J.¹, Song W.¹, Chen Y.¹, Chen X.¹, Shang H.¹
¹Neurology, West China Hospital, Sichuan University, Chengdu, China
- P-145** Effect of diabetes mellitus on development of Parkinson's disease
Kim W.C.¹
¹Neurology, CHA Bundang Medical Center, Seongnam, Republic of Korea
- P-146** BDNF Val66Met polymorphism is associated with verbal memory dysfunction in Parkinson's disease
Hong J.H.¹, Kim Y.J.², Park J.S.², Kim Y.E.³, Ye B.S.⁴, Yoo W.-K.⁵, Ma H.-I.³, Kim Y.J.¹
¹ILSONG Institute of Life Science, Hallym University, Anyang, Republic of Korea, ²Department of Neurology, Hallym University College of Medicine, Chuncheon, Republic of Korea, ³Department of Neurology, Hallym University Sacred Hospital, Anyang, Republic of Korea, ⁴Department of Neurology, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁵Department of Physical Medicine & Rehabilitation, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea

- P-147** Prevalence of Parkinson disease in the city of South Delhi, India
Shahi A.¹, Sharma V.¹
¹Shri Maha Maya Vaishnav Devi Mandir Research Institute, Applied Sciences, New Delhi, India
- P-148** Diagnostic accuracy of freezing index with wearable accelerometer for detecting freezing of gait in Parkinson's disease
Park J.¹
¹Department of Neurology, Haundae Paik Hospital, Busan, Republic of Korea
- P-149** Non-motor predictors of early manifestations of Parkinson's disease
Azizova R.¹, Shakur M.²
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan, ²Department of Neurology, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan
- P-150** The role of the endothelial growth factor (EGF) in Parkinson disease
Fakhrgaliev S.¹, Azizova R.¹
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-151** Implementation of cloud technologies for prediction of morbidity from Parkinson's disease and optimization of medical resources
Ishmatova S.¹, Turgunkhujayev O.²
¹Moscow Polytechnical University, Moscow, Russian Federation, ²Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-152** Features of P300 cognitive potentials in Parkinson's disease
Ruzimurodov N.¹, Umarov A.¹
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-153** Gender-age features of autonomic heart rhythm disturbances in Parkinson's disease patients
Solodovnikova Y.¹
¹Neurology, Odessa National Medical University, Odessa, Ukraine
- P-155** Positional asphyxia, the rare but fatal complication of nocturnal hypokinesia: a case report
Sringean J.¹, Jakota P.^{1,2}, Bhidayasiri R.¹
¹Medicine, Chulalongkorn University, Bangkok, Thailand, ²Medicine, Chulalongkorn, Bangkok, Thailand
- P-156** Patient-related factors' impact on caregiver burden in Parkinson's disease in Singapore
Lim E.C.¹, Tan M.J.M.², Nadkarni N.³, Lye W.K.³, Prakash K.M.^{1,4}, Tan E.K.^{1,4}
¹Neurology, National Neuroscience Institute (SGH campus), Singapore, Singapore, ²DUKE-NUS Graduate Medical School, Singapore, Singapore, ³Centre of Quantitative Medicine, DUKE-NUS Graduate Medical School, Singapore, Singapore, ⁴Neurology, Singapore General Hospital, Singapore, Singapore
- P-157** "Dynamic DAT" imaging is useful for diagnoses of parkinsonism with dementia
Abe K.¹, Fukushima K.², Maeda Y.³, Yoshikawa H.¹
¹Neurology, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Nuclear Medicine and PET, Hyogo Medical College Hospital, Nishinomiya, Japan, ³Department of Radiological Technology, Hyogo Medical College Hospital, Nishinomiya, Japan

Topic: Parkinson 2

P-158 Long-duration response to levodopa in advanced Parkinson's disease: relevance for RCT on disease-modifying therapies

Cilia R.¹, Cereda E.², Amboni M.^{3,4}, Akpalu A.⁵, Sarfo F.S.⁶, Cham M.⁷, Fabbri M.⁸, Pezzoli G.¹

¹Parkinson Institute, ASST Gaetano Pini-CTO, Milan, Italy, ²Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ³Department of Medicine and Surgery, University of Salerno, Salerno, Italy, ⁴IDC Hermitage-Capodimonte, Naples, Italy, ⁵Korle Bu Teaching Hospital, Accra, Ghana, ⁶Komfo Anokye Teaching Hospital, Kumasi, Ghana, ⁷Comboni Hospital, Sogakope, Ghana, ⁸IRCCS Institute of Neurological Sciences, Bologna, Italy

P-159 Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF-episodes in subjects with Parkinson's disease: preliminary results from the Phase 3 study dose titration phase

Fernandez H.H.¹, Isaacson S.², Espay A.J.³, Pahwa R.⁴, Truong D.⁵, Pappert E.⁶, Agro A.⁷, Hauser R.A.⁸

¹Neurology, Center for Neurological Restoration, Cleveland Clinic, Cleveland, United States, ²Neurology, Parkinson's Disease & Movement Disorders Center of Boca Raton, Boca Raton, United States, ³Neurology, University of Cincinnati, Cincinnati, United States, ⁴Neurology, University of Kansas Medical Center, Kansas City, United States, ⁵Neurology, the Parkinson's & Movement Disorders Institute, Fountain Valley, United States, ⁶Neurology Associates, San Antonio, United States, ⁷Pathology & Molecular Medicine, McMaster University, Hamilton, Canada, ⁸Neurology, University of South Florida, Tampa, United States

P-161 Long-term pulmonary safety of inhaled levodopa in Parkinson's disease subjects with motor fluctuations: interim results of a phase 3 study

Grosset D.¹, Dhali R.², Gurevich T.³, Kassubek J.⁴, Poewe W.⁵, Rascol O.⁶, Rudzińska-Bar M.⁷, Cormier J.⁸, Sedkov A.⁹, Oh C.⁸

¹Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom, ²University of Arkansas for Medical Sciences, Little Rock, United States, ³Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁴University of Ulm, Ulm, Germany, ⁵Innsbruck Medical University, Innsbruck, Austria, ⁶University of Toulouse, Toulouse, France, ⁷Medical University of Silesia, Katowice, Poland, ⁸Acorda Therapeutics, Inc., Ardsley, United States

P-162 Mobility in people with Parkinson's disease with different medication profile

Faucher G.¹, Brière S.², Blamoutier M.¹, Roofigari N.¹, Nguyen H.P.¹, Bogard S.¹, Goubault E.¹, Duval C.¹

¹Département des Sciences de l'activité physique, Université du Québec à Montréal, Montréal, Canada, ²Centre de Recherche sur le Vieillessement de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Canada

P-163 Detection, segmentation, and assessment of daily living activities using inertial sensor in people with Parkinson's disease during a cleaning task

Duval C.¹, Nguyen H.P.¹, Lebel K.², Bogard S.¹, Goubault É.¹, Clinicians Q.P.N.³, Boissy P.²

¹Département des Sciences de l'activité physique, Université du Québec à Montréal, Montreal, Canada, ²Département de chirurgie, Université de Sherbrooke, Sherbrooke, Canada, ³Quebec Parkinson Network, Montreal, Canada

- P-164 Rehabilitative experience with motor imagery in progressive supranuclear palsy – a case report**
Kaur D.¹, Kumar G.², Kumar Singh A.³
¹Dept. of Neurorehabilitation, Bihar Neurodiagnostic Centre, Patna, India, ²Neurology, All India Institute of Medical Sciences (AIIMS), Patna, India, ³Neurology, Bihar Neurodiagnostic Centre, Patna, India
- P-165 Investigation to expand application sites of rotigotine transdermal patch**
Kujirai H.¹, Aoyama H.¹, Hagiwara W.¹, Abe K.¹, Takahashi M.¹, Inaba A.¹, Orimo S.¹
¹Neurology, Kanto Central Hospital, Tokyo, Japan
- P-166 Tele-health for patients with deep brain stimulation: a retrospective chart review**
Jitkritisadaku O.^{1,2}, Rajalingam R.², Toenjes C.³, Munhoz R.P.², Fasano A.²
¹Chulalongkorn University, Department of medicine, Bangkok, Thailand, ²Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University of Toronto, Toronto, Canada, ³Telehealth program, University of Toronto, Toronto, Canada
- P-167 The effect of levodopa treatment on endothelial function in patients with Parkinson's disease: serial flow-mediated dilation studies**
Yoon J.¹, Kil Y.-E.²
¹Ajou University Hospital, Suwon, Republic of Korea, ²Neurology, Suwon, Republic of Korea
- P-168 Dopamine dysregulation syndrome and deep brain stimulation in patients with Parkinson's disease**
Omarova S.¹, Fedorova N.¹, Tomskiy A.², Gamaleya A.², Bril E.¹
¹Department of Neurology, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation, ²Department of Neurosurgery, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation
- P-169 Tetrahydroisoquinoline molecule of Indian ayurveda medicine: therapeutic potential in Parkinson's disease**
Banerjee R.¹, Raju A.¹, Ngima Nthenge-Ngumbau D.¹, Singh R.¹, Jaisankar P.¹, Mohanakumar K.P.¹, Biswas S.C.¹
¹Cell Biology & Physiology, CSIR-Indian Institute of Chemical Biology, Kolkata, India
- P-170 Role of anticholinergic medications in treatment of Parkinson's disease**
Mishima T.¹, Fujioka S.¹, Yamaguchi Y.¹, Hayashi Y.¹, Onozawa R.¹, Fukae J.¹, Tsuboi Y.¹
¹Neurology, Fukuoka University, Fukuoka, Japan
- P-171 Parkinson disease therapy during Ramadhan fasting month. A case report**
Abdul Halim S.¹
¹Department of Medicine, Universiti Sains Malaysia, Kelantan, Malaysia
- P-172 A potential therapeutic option for postural deformities in Parkinson disease**
Nose K.¹, Fujioka S.¹, Yoshida R.², Hayashi Y.¹, Kitano K.², Maruyama S.², Kikuchi H.², Tsuboi Y.¹
¹Fukuoka University, Fukuoka, Japan, ²Murakamkarindoh Hospital, Fukuoka, Japan

- P-173 Electric stimulation evoked potential of subthalamic nucleus in deep brain stimulation surgery: a preliminary study**
Lin S.-H.^{1,2}, Chen S.-Y.³, Jaw F.-S.²
¹Department of Neurology, Tzu Chi hospital/University, Hualien, Taiwan, Republic of China, ²Institute of biomedical engineering, National Taiwan University, Taipei, Taiwan, Republic of China, ³Department of Neurosurgery, Tzu-Chi hospital/University, Hualien, Taiwan, Republic of China
- P-174 Long term result and safety of the subthalamic nuclear DBS of advanced Parkinson's disease: an eight year follow up study**
Guo Q.¹, Chen L.¹
¹Neurology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, China
- P-175 Stress response of autonomic nervous system during conditioned inhalation general anesthesia for deep brain stimulation**
Chen S.Y.¹, Lin S.H.², Tsai S.T.³
¹Neurosurgery, Tzu Chi General Hospital / University, Hualien, Taiwan, Republic of China, ²Neurology, Tzu Chi General Hospital / University, Hualien, Taiwan, Republic of China, ³Neurosurgery, Tzu Chi General Hospital, Hualien, Taiwan, Republic of China
- P-176 The effectiveness of neurometabolic treatment of Parkinson's disease (PD) and vascular parkinsonism**
Ruzimurodov N.¹, Tolibov D.¹, Mirzaeva D.¹
¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-177 Evaluations of additive effect of two Indigenous medicinal plants Cedrus deodara and Mucuna pruriens towards the treatment of Parkinson's disease**
Jain S.¹, Jain A.¹
¹Pharmacy, Bhagyoday Tirth Pharmacy College, Sagar, India
- P-178 The effect of the Nordic walking on motor functions in Parkinson's disease**
Stożek J.¹, Rudzińska-Bar M.², Staszczak-Gawęda I.³, Podsiadło S.³, Stenwak A.⁴, Świątek K.⁵, Pustułka- Piwnik U.⁵, Szczudlik A.⁴
¹Department of Clinical Rehabilitation, University School of Physical Education, Krakow, Poland, ²Department of Neurology, Katowice, Poland, ³PhD studies, Krakow, Poland, ⁴Department of Neurology, Krakow, Poland, ⁵Department of Clinical Rehabilitation, Krakow, Poland
- P-179 UPDRS III and reflexive saccades latency indicate that STN DBS has therapeutic neuromodulatory effects in Parkinson's disease**
Szlufik S.¹, Przybyszewski A.², Dutkiewicz J.¹, Habela P.², Mandat T.³, Koziorowski D.¹
¹Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland, ²Department of Informatics, Polish Japanese Academy of Information Technology, Warsaw, Poland, ³Department of Neurosurgery, Institute of Psychiatrics and Neurology, Warsaw, Poland

P-180 STN DBS can temporarily improve balance disorders in Parkinson's disease patients

Szlufik S.¹, Kloda M.^{1,2}, Potrzebowska I.¹, Gregier K.¹, Przybyszewski A.³, Dutkiewicz J.¹, Habela P.³, Mandat T.⁴, Bialoszewski D.², Koziarowski D.¹

¹Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland, ²Department of Rehabilitation, II Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland, ³Department of Informatics, Polish Japanese Academy of Information Technology, Warsaw, Poland, ⁴Department of Neurosurgery, Institute of Psychiatric and Neurology, Warsaw, Poland

P-181 Neuromodulation by rTMS in Parkinson's disease

Goyal V.¹, Priyanka B.¹, Srivastava A.K.¹, Kumaran S.S.²

¹Department of Neurology, AIIMS, New Delhi, India, ²Department of NMR, AIIMS, New Delhi, India

P-182 Case reports: repetitive transcranial magnetic stimulation (rTMS) therapy for Parkinson's disease (PD)

Toyoda C.¹, Ikeda M.¹, Sakai K.¹, Omoto S.¹, Iguchi Y.¹, Kimura I.², Abo M.²

¹Neurology, The Jikei University School of Medicine, Tokyo, Japan, ²Rehabilitation Medicine, The Jikei University School of Medicine, Tokyo, Japan

P-183 Prevalence of and indications for antipsychotic use in Parkinson disease

Bower J.¹, Grossardt B.², Rocca W.², Savica R.¹

¹Neurology, Mayo Clinic, Rochester, United States, ²Health Sciences Research, Mayo Clinic, Rochester, United States

P-184 Rehabilitation program with or without muscle-targeted nutritional support in patients with Parkinson's disease or parkinsonism: study design of a randomized, controlled trial

Barichella M.¹, Cereda E.², Pinelli G.¹, Caroli D.¹, Masiero I.¹, Negri S.J.¹, Ferri V.¹, Iorio L.¹, Cassani E.¹, Riboldazzi G.³, Frazzitta G.⁴, Pezzoli G.¹

¹ASST G. Pini-CTO, ex-ICP, Parkinson Institute, Milano, Italy, ²Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ³U.S. Riabilitazione Parkinson, Fondazione Gaetano e Piera Borghi di Brebbia, Brebbia, Italy, ⁴Dipartimento Riabilitazione Malattia di Parkinson e Disturbi del Movimento, Ospedale Classificato Moriggia Pelascini di Gravedona, Gravedona, Italy

P-185 Assessment of the quality of life of patients with Parkinson's disease with chronic pain syndrome

Umarov A.¹, Rakhimbaeva G.¹

¹Department of Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan

Topic: Parkinsonian Syndromes

- P-186** Influence of medial temporal lobe atrophy on the progress of cognitive impairment in patient with dementia with Lewy bodies
Matsuda Y.¹, Uchida K.¹, Ohtomo T.¹, Maruta J.¹, Inoue K.¹
¹Neuropsychiatry, Osaka City University Graduate School of Medicine, Osaka, Japan
- P-187** Synchronicity of climate fluctuation with daily activity of alpha synucleinopathic patients.
Turgunkhujaev O.¹, Tolibova N.¹
¹Neurology, Tashkent Medical Academy, Tashkent, Uzbekistan
- P-188** An example for drug-disease interaction: cardiac side effects related to rivastigmine in a patient with Lewy body dementia
Celik T.¹, Isik A.T.², Kaya D.², Soysal P.², Kadioglu B.¹
¹Department of Pharmacology, Yeditepe University, Istanbul, Turkey, ²Department of Geriatric Medicine, Dokuz Eylul University, Izmir, Turkey
- P-189** The identification of molecular-genetic background of familial atypical parkinsonism in "Hornacko", a specific region of the south-eastern Moravia, Czech Republic
Mensikova K.¹, Vodicka R.², Kolarikova K.², Bartonikova T.¹, Mikulicova L.¹, Kaiserova M.¹, Vastik M.¹, Vrtel R.², Otruba P.¹, Bares M.³, Janout V.⁴, Kanovsky P.¹
¹Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, University Hospital, Olomouc, Czech Republic, ²Department of Clinical and Molecular Genetics, Faculty of Medicine and Dentistry, Palacky University, University Hospital, Olomouc, Czech Republic, ³Department of Neurology, Masaryk University Medical School, St. Anne University Hospital, Brno, Czech Republic, ⁴Department of Epidemiology and Public Health, Faculty of Medicine and Dentistry, Palacky University, University Hospital, Olomouc, Czech Republic
- P-190** 11C-CFT-PET in presymptomatic FTDP-17: a potential biomarker predicting onset
Liu J.¹, Wu L.¹, Feng X.¹, Dong J.¹, Qin W.¹, Jia J.¹
¹Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
- P-191** Executive dysfunction, behavioral changes and quality of life in Chinese patients with progressive supranuclear palsy
Qu R.¹, Liu H.¹, Hou Y.¹, Wei Q.¹, Cao B.¹, Zhao B.¹, Shang H.¹
¹Neurology, West China Hospital, Sichuan University, Chengdu, China
- P-192** Deep brain stimulation therapy of levodopa-responsive motor fluctuations in patients with multiple system atrophy
Hedera P.¹, Claassen D.²
¹Vanderbilt University, Department of Neurology, Nashville, United States, ²Neurology, Nashville, United States
- P-193** The MRI-based brain structure measurements in Parkinson's disease and Parkinson-plus syndromes
Peng S.¹, Liang Y.¹, Jing X.¹, Chen Y.¹, Lin D.¹, Bu C.², Zheng D.¹, Huang K.¹, Lei M.¹, Xiao S.¹, Yang L.¹, Liu J.¹, Huang S.², Tao E.¹
¹Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ²Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

- P-194 A case of progressive supranuclear palsy confused with alcohol-related dementia**
Maruta J.¹, Matsuda Y.¹, Ohtomo T.¹, Uchida K.¹, Inoue K.¹
¹Neuropsychiatry, Osaka City University Graduate School of Medicine, Osaka city, Osaka, Japan
- P-196 Comparative analysis of sleep disorders between groups of patients with Parkinson's disease and Parkinson's syndrome**
Djalilova S.¹
¹Neurology, Tashkent medical Academy, Tashkent, Uzbekistan
- P-197 Differential diagnosis of Parkinson's disease and multiple system atrophy**
Trufanov Y.¹
¹Neurology, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
- P-198 Clinical characteristics and quality of life in Chinese patients with multiple system atrophy**
Du J.¹, Wang T.¹, Chen S.¹
¹Department of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
- P-199 Survival analysis and prognostic nomogram in multiple system atrophy**
Cao B.¹, Zhang L.¹, Zou Y.², Wei Q.¹, Ou R.¹, Chen Y.¹, Yang J.¹, Wu Y.¹, Shang H.¹
¹Neurology, West China Hospital, Sichuan University, Chengdu, China, ²West China School of Medicine, Sichuan University, Chengdu, China
- P-200 Postural instability in ambulatory Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA), possible different mechanism from Parkinson's disease**
Panyakaew P.¹, Bhidayasiri R.¹
¹Chulalongkorn Center of Excellence for Parkinson's Disease and Related Disorders, Bangkok, Thailand
- P-201 Validation of the Korean version of the Composite Autonomic Symptom Scale-31 (COMPASS-31)**
Kim Y.¹, Seok J.M.², Youn J.^{3,4}, Min J.-H.^{3,4}, Cho J.W.^{3,4}, Kim B.J.^{3,4}
¹Neurology Department, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea, ²Neurology Department, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea, ³Neurology Department, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁴Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea
- P-202 Walking on a bamboo stick: a self-invented tactile cue for freezing of gait in a patient with Parkinson's disease**
Rattanachaisit W.¹, Bhidayasiri R.²
¹Chulalongkorn Center of Excellence for Parkinson Disease and Related Disorders, Chulalongkorn University, Bangkok, Thailand, ²Chulalongkorn Center of Excellence for Parkinson's Disease and Related Disorders, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

P-203 A novel MAPT mutation in a family of PSP look-alike phenotype

Park J.¹, Na B.S.², Kim Y.³, Cho J.W.²

¹Department of Neurology, Soonchunhyang University Hospital, Gumi, Republic of Korea, ²Department of Neurology, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea, ³Department of Neurology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea



INFORMATION FOR SPEAKERS

POWERPOINT INSTRUCTIONS

Please use Microsoft PowerPoint 97-2007, 2010 or 2013* (*.ppt) or (*.pptx), or Adobe Acrobat Reader (.pdf) to guarantee slides will open successfully on an on-site PC. Prepare your presentation in 16:9 or 4:3 format (screens are in 16:9 aspect).

PICTURES/VIDEOS

JPG images are the preferred file format for inserted images. GIF, TIF or BMP formats will be accepted as well.

Images inserted into PowerPoint are embedded into the presentations. Images that are created at a dpi setting higher than 200 dpi are not necessary and will only increase the file size of your presentation. Try to avoid overloading your presentation with unnecessary images.

In case you have any videos in your presentation, please test your presentation with the on-site PC several hours before your presentation. Generally, the MPEG-1 and AVI format should work with no difficulties.

HOW TO SAVE YOUR PRESENTATION

Please save your presentation in one of the following:

- External portable hard drive
- USB flash drive

HOW TO SUBMIT YOUR PRESENTATION ON-SITE

Please come to the Media Check on Level 4 at least 1,5 hours before the beginning of your session. If your speech has been scheduled for the morning session, please come to the Media Check one day before the day of your presentation.

Use of own technical equipment (e.g. laptop, presenter, projector, etc.) is not allowed.

WE STRONGLY ASK ALL SPEAKERS TO KEEP WITHIN THE TIME LIMIT FOR YOUR PRESENTATION!

INFORMATION FOR ABSTRACT AUTHORS

POSTER EXHIBITION

We kindly ask you to prepare your poster in the following format:

Format: Upright Format (DIN A0)

Max. Height: 118,9 cm / 46,8 inch

Max. Width: 84,1 cm / 33,1 inch

Language: English

Where: Exhibition Hall – please look for your poster number: P-XXX or OP-X-XX

- Posters in a horizontal format will not be accepted or displayed.
- Material for hanging up the posters will be provided on-site at the poster area.
- The use of technical equipment is not permitted.

We kindly ask all poster authors to be available at their posters in order to enable visits and talks with participants during the following times:

Monday, 13 November 2017 from 12:15 – 13:00 pm (during lunch break)

Tuesday, 14 November 2017 from 12:15 - 13:00 pm (during lunch break)

ORAL POSTER PRESENTATION

Please note that the time allocated for your presentation is a short 4-minute oral presentation followed by 2 minutes Q&A. Given that there are additional abstracts presenting in the same session, we urge you not to exceed the time limit in order to give the other speakers time for their talks.

Important Information:

The Oral Poster Session will take place in the form of a poster walk. The oral presentation will be directly beside your poster. In order to find your poster wall with your corresponding poster number on-site, please see the exhibition plan or ask our staff at the poster exhibition.

No PowerPoint Slides for presentation or further technical equipment like laptops are needed.

WE STRONGLY ASK ALL SPEAKERS TO KEEP WITHIN THE TIME LIMIT FOR YOUR PRESENTATION!

Please note the time slots for set-up and removal of posters:

The posters for the Poster Area must be hung up on Sunday, 12 November between 10:00 am – 13:00 pm.

Presenters of an Oral Poster are kindly ask to hang up their posters within the Poster Islands in Exhibition.

Please take down your poster on Wednesday, 15 November between 10:30 am – 13:00 pm.

All posters that have not been taken down by this time will be removed and disposed of by the congress staff!

INDEX OF AUTHORS AND SPEAKERS

A

Acharya, Mrinal Kumar (Kolkata, India)	13
Aguilar, Jose (Metro Manila, Philippines)	23
Ahmad, Istaq (Delhi, India)	14
Akbostanc, Muhittin (Ankara, Turkey)	39
Alberts, Jay (Cleveland, United States)	30
Antonini, Angelo (Venice, Italy)	23, 31
Aybek, Selma (Bern, Switzerland)	36
Azulay, Jean-Philipp (Marseille, France)	30, 35

B

Baik, Jong Sam (Seoul, Republic of Korea)	25
Bajenaru, Ovidiu (Bucharest, Romania)	63, 113
Bajwa, Jawad (Riyadh, Saudi Arabia)	31, 47
Barua, Amit Ranjan (Guwahati, India)	13
Baumann, Christian (Zurich, Switzerland)	6, 40, 47
Bernal-Pacheco, Oscar (Bogóta, Colombia)	34
Bertoni, John (Omaha, United States)	5
Bhargava, Mani (Kanpur, India)	60
Bhatia, Kailash (London, United Kingdom)	36
Bhidayasiri, Roongroj (Bangkok, Thailand)	24, 31, 33
Bloem, Bastiaan (Nijmegen, The Netherlands)	22
Bodis-Wollner, Ivan (Brooklyn, United States)	22, 47
Bogard, Sarah (Montréal, Canada)	32
Bonifati, Vincenzo (Rotterdam, The Netherlands)	46, 49
Borgohain, Rupam (Hyderabad, India)	33
Bruecke, Thomas (Vienna, Austria)	23, 37

C

Cereda, Emanuele (Pavia, Italy)	18, 30, 71
Chang, Ming-Hong (Taichung, Taiwan)	18
Chen-Plotkin, Alice (Philadelphia, United States)	15

Chen, Sheng-Di (Shanghai, China)	22, 46
Chen, Yimeng (Shanghai, China)	36
Choudhury, Supriyo (Kolkata, India)	48
Cilia, Roberto (Milano, Italy)	23, 36, 68
Colosimo, Carlo (Terni, Italy)	12, 20
Comella, Cynthia (Chicago, United States)	33, 34, 113
Cui, ShiShuang (Shanghai, China)	25
Cusso, Melanie (Southport, Australia)	19

D

Dang, Thi Huyen Thuong (Ho Chi Minh City, Vietnam)	38, 62
De Baat, Cees (Oegstgeest, The Netherlands)	25
Deng, Xiao (Nanning, China)	25
Dickson, Dennis (Jacksonville, United States)	21, 46
Diesta, Cid (Quezon City, Philippines)	36
DiRocco, Alessandro (New York, United States)	41
Dressler, Dirk (Hannover, Germany)	32, 40, 48

E

Espay, Alberto (Cincinnati, United States)	13, 24, 32, 40, 112, 113
--	--------------------------

F

Fahn, Stanley (New York, United States)	15, 23, 40
Fasano, Alfonso (Toronto, Canada)	41, 47
Fernandez, Hubert (Cleveland, United States)	34, 68, 112, 113
Franco, Giulia (Nashville, United States)	49
Frei, Karen (Loma Linda, United States)	20, 48, 112
Friedman, Andrzej (Warsaw, Poland)	24
Friedman, Joseph (Rhode Island, United States)	12, 21, 112
Frolova, Monika (Olomouc, Czech Republic)	39
Fujioka, Shinsuke (Fukuoka, Japan)	12, 19, 48

INDEX OF AUTHORS AND SPEAKERS

G

Gamaleya, Anna (Moscow, Russian Federation)	33
Gams Massi, Daniel (Dakar, Senegal)	18
Golpich, Mojtaba (Kuala Lumpur, Malaysia)	13
Goubault, Etienne (Chengdu, China)	19
Gray, David (Cambridge, United States)	33
Gu, Xiaojing (Chengdu, China)	39
Guo, Jifeng (Changsha, China)	25

H

Hallett, Mark (Bethesda, United States)	34, 36, 47
Han, Qing (Chengdu, China)	13
Hasegawa, Kazuko (Sagamihara, Japan)	37
Hattori, Nobutaka (Tokyo, Japan)	12
Helmich, Rick (Nijmegen, The Netherlands)	36, 40
Hirsch, Etienne (Paris, France)	14
Hong, Chien Tai (New Taipei City, Taiwan)	18
Huang, Pei (Shanghai, China)	18

I

Ikeuchi, Takeshi (Niigata, Japan)	21
Isaacson, Stuart (Boca Raton, United States)	21, 24
Isaias, Ioannis (Wuerzburg, Germany)	25, 40

J

Jankovic, Joseph (Houston, United States)	34, 41
Jeon, Beom (Seoul, Republic of Korea)	22, 30
Jimenez-Shahed, Joohi (Houston, United States)	23, 32, 40
Jinnah, Hyder (Atlanta, United States)	31, 32
Jitkriksadikul, Onanong (Bangkok, Thailand)	37, 69

K

Kaji, Ryuji (Tokushima, Japan)	46
Kalia, Lorraine (Toronto, Canada)	13, 15, 19
Kamble, Nitish (Bangalore, India)	13
Kamenova, Saltanat (Almaty, Kazakhstan)	40, 62
Kaufmann, Horaico (New York, United States)	20
Khajibakiev, Khakim (Tashkent, Uzbekistan)	39
Kim, Aleksandr (Moscow, Russian Federation)	37
Kim, Jinho (Gwanju, Republic of Korea)	25
Kim, Yana (Almaty, Kazakhstan)	60, 73
Kmiec, Tomasz (Warszawa, Poland)	49
Koprich, James (Toronto, Canada)	13
Koszewicz, Magdalena (Wroclaw, Poland)	32
Krauss, Joachim (Hannover, Germany)	12, 15, 23, 31

L

Lackovic, Zdravko (Zagreb, Croatia)	13
Le, Minh (Ho Chi Minh City, Vietnam)	30, 37
Le, Weidong (Dalian, China)	19, 60
Lebel, Karina (Sherbrooke, Canada)	37
LeDoux, Mark (Memphis, United States)	14, 42, 53
Lew, Mark (Los Angeles, United States)	20, 23
Lim, Jia Lun (Kuala Lumpur, Malaysia)	18
Lim, Sehn-Yang (Kuala Lumpur, Malaysia)	24, 31
Lim, Seong Hoon (Kyungki-Do, Republic of Korea)	18
Lim, Thien T. (George Town, Malaysia)	34, 41
Ling, Helen (London, United Kingdom)	21
Liu, Hui (Chengdu, China)	19, 25
Liu, Wanglin (Chengdu, China)	48
Louis, Elan (New Haven, United States)	33, 40

INDEX OF AUTHORS AND SPEAKERS

M

Ma, Hyeo-II (Anyang, Republic of Korea)	13
Ma, Lin (Beijing, China)	38
Macas, Mabel (Manila, Philippines)	25, 48
Madathiparambil Radhakrishnan, Divya (Delhi, India)	36
Maguire, Gerald A. (Riverside, United States)	113
Meissner, Wassilios (Bordeaux, France)	19, 32
Melo, Ailton (Salvador, Brazil)	20, 22
Mestre, Tiago (Ottawa, Canada)	35, 38
Mondal, Banashree (Kolkata, India)	33
Moro, Elena (Grenoble, France)	15, 22, 23, 36
Mridula, Rukmini (Panjagutta, India)	41
Mueller, Thomas (Berlin, Germany)	24

N

Na, Boo Suk (Seoul, Republic of Korea)	39
Nakano, Yoshikazu (Chiba, Japan)	26
Narang, Manpreet Kaur (New Delhi, India)	49
Nasirova, Iroda (Tashkent, Uzbekistan)	14
Ness, Daniel K. (South San Francisco, United States)	37
Nevrlý, Martin (Olomouc, Czech Republic)	49
Ng, Shin Hui (Singapore, Singapore)	18, 62
Nguyen, Hung Trong (Hanoi, Vietnam)	20
Nguyen, Huu Cong (Ho Chi Minh City, Vietnam)	37
Nguyen, Thanh Binh (Hanoi, Vietnam)	38
Nguyen, Van Lieu (Hanoi, Vietnam)	38
Nicole Chia, Shuang Yu (Singapore, Singapore)	25

O

Oh, Charles (Ardsley, United States)	32
Oh, Young Jun (Seoul, Republic of Korea)	46
Ojo, Oluwadamilola (Lagos, Nigeria)	34
Ondo, William (Houston, United States)	47, 113

P

Pahwa, Rajesh (Kansas City, United States)	24, 40
Pal, Pramod (Bengaluru, India)	22, 39
Park, Young Min (Seoul, Republic of Korea)	26
Peretz, Chava (Tel Aviv, Israel)	19, 39
Pezzoli, Gianni (Pavia, Italy)	32
Pfeiffer, Ronald (Portland, United States)	20, 49
Pham, Anh Tuan (Ho Chi Minh City, Vietnam)	38
Pisani, Antonio (Rome, Italy)	14, 18
Prasad, Shweta (Bangalore, India)	48
Puschmann, Andreas (Lund, Sweden)	12, 49

R

Rabey, Jose Martin (Tel Aviv, Israel)	48
Rakhimbaeva, Gulnora (Uzbekistan)	35
Rattanachaisit, Watchara (Bangkok, Thailand)	74
Reichmann, Heinz (Dresden, Germany)	35, 41
Rektor, Ivan (Brno, Czech Republic)	8
Rektorova, Irena (Brno, Czech Republic)	21, 25
Relja, Maja (Zagreb, Croatia)	35, 56
Riederer, Peter (Wuerzburg, Germany)	21, 46
Rodriguez, Ramon (Gainesville, United States)	31, 42
Rosales, Raymond (Quezon City, Philippines)	31, 35, 42
Roth, Jan (Praha, Czech Republic)	34, 47
Roy, Akash (Kolkata, India)	48
Rukmani, Malligurki Raghurama (Bangalore, India)	38

S

Sakdisornchai, Karn (Bangkok, Thailand)	33
Samat, Nor Aslina (Cheras, Malaysia)	38
Samuel Ng, Yong Ern (Singapore, Singapore)	32
Sandroni, Paola (Rochester, United States)	41, 48

INDEX OF AUTHORS AND SPEAKERS

Setiawan, Fiona (Singapore, Singapore)	48
Shang, Hui-Fang (Chengdu, China)	12, 20
Shannon, Kathleen (Madison, United States)	22, 35
Sharma, Vinod (New Delhi, India)	32
Siegert, Scott (San Diego, United States)	37, 48
Simuni, Tanya (Chicago, United States)	14, 19, 113
Singer, Carlos (Miami, United States)	14, 30, 36
Singh, Himanshu Narayan (Delhi, India)	48
Singh, Inder (New Delhi, India)	13
Sohn, Young H. (Seoul, Republic of Korea)	18
Soloveva, Maria (Melbourne, Australia)	49
Sonakar, Akhilesh Kumar (New Delhi, India)	14
Srivastava, Achal (New Delhi, India)	47
Stefani, Alessandro (Rome, Italy)	33
Stocchi, Fabrizio (Rome, Italy)	22, 33
Stoessl, Jon (Vancouver, Canada)	12, 23
Strafella, Antonio P. (Toronto, Canada)	112
Surmeier, James (Chicago, United States)	20
Swarup, Vishnu (New Delhi, India)	13
Sy, Michelle Ann C. (Manila, Philippines)	26

T

Tagliati, Michele (Los Angeles, United States)	30
Takkar, Amit (Delhi, India)	13
Tan, Ai Huey (Kuala Lumpur, Malaysia)	26
Tan, Eng-King (Singapore, Singapore)	21, 49
Tangkanakul, Chanya (Pathumthani, Thailand)	18
Tanner, Caroline (San Francisco, United States)	14, 32, 47
Teh, Pei Chiek (Wilayah Persekutuan Kuala Lumpur, Malaysia)	36
To Thi Bich, Phuong (Tel Aviv, Israel)	19
Torres-Russotto, Diego (Omaha, United States)	30, 37, 41
Tousi, Babak (Cleveland, United States)	39

Tran, Cong Thang (Ho Chi Minh City, Vietnam)	38
Tran, Ngoc Tai (Ho Chi Minh City, Vietnam)	37, 38
Tran, Tai (Ho Chi Minh, Vietnam)	30, 42, 48
Truong, Daniel (Fountain Valley, United States)	15, 26, 34, 37, 42, 49
Turaeva, Guzai (Tashkent, Uzbekistan)	51

V

Valldeoriola, Francesc (Barcelona, Spain)	12, 19
Van Wegen, Erwin (Amsterdam, The Netherlands)	24
Vidailhet, Marie (Paris, France)	32
Vo Nguyen Ngoc, Trang (Ho Chi Minh, Vietnam)	36, 39, 40, 56

W

Weintraub, Daniel (Philadelphia, United States)	20, 21
Wolters, Erik Ch. (Amsterdam, The Netherlands)	14, 15
Wszolek, Zbigniew (Jacksonville, United States)	46, 49
Wu, Ruey-Meei (Taipei, Taiwan)	46
Wu, Tsai Ling (Taipei, Taiwan)	25
Wu, Yih-Ru (Taoyuan, Taiwan)	31

Y

Yan, Jin (Shenzhen, China)	18
Yarden, Jennifer (Haifa, Israel)	15
Yu, Xin Xin (Cleveland, United States)	40
Yuan, Xiaoqin (Chengdu, China)	39

Z

Zhang, Lingyu (Chengdu, China)	39
Zhang, Xiao Jin (Singapore, Singapore)	38, 58

ABSTRACT E-BOOK IS NOW PROVIDED AS DOWNLOAD!



The Abstract Book contains all accepted abstracts that have been submitted by authors from around the globe on topics related to Parkinson disease and other movement disorders.

All abstracts have been reviewed by a panel of reviewers.

To quote abstracts, use the following information:

Abstract Title

Abstract Number

Author Name

Source: XXII World Congress on Parkinson's Disease and Related Disorders

Ho Chi Minh City, Vietnam, 12 – 15 November 2017

URN: 1234567890

Copyright ©2017 International Association of Parkinsonism and Related Disorders

IAPRD CONGRESS AWARDS

CONGRESS AWARDS

Melvin Yahr Travel Awards

Melvin Yahr Young Investigator Awards

Best Presentation: Clinical Science of Movement Disorders

Best Presentation: Basic Science of Movement Disorders

Best Presentation by a Woman in Movement Disorders

Oral Poster Awards

Winners of the Melvin Yahr Young Investigator Awards will be officially announced in the Plenary Session on Wednesday, 15 November at 11:45 am.

AWARDS COMMITTEE

IAPRD AWARDS

Chair: Mark Lew (United States)

Jasem Al-Hashel (Kuwait)

Hung Trong Nguyen (Vietnam)

Thien Thien Lim (Malaysia)

Diego Torres-Russotto (United States)

MELVIN YAHR AWARDS

Chair: Elena Moro (France)

Melvin Yahr Foundation Scientific Committee



GENERAL CONGRESS INFORMATION



REGISTRATION

REGISTRATION COUNTER – HOURS

Sunday, 12 November 2017	9:00 am – 19:00 pm
Monday, 13 November 2017	7:30 am – 17:30 pm
Tuesday, 14 November 2017	7:30 am – 19:30 pm
Wednesday, 15 November 2017	7:30 am – 12:30 pm

REGISTRATION FEES

Registration Types	On-site Price
Regular Congress Ticket*	€ 750,00
Reduced Fee**	€ 500,00
Student Ticket***	€ 400,00
Congress Dinner	€ 85,00

* Special conditions for Travel Grant applicants. See further information and conditions under “General Information/ Travel Grants”, Page 92

** Participants from lower & lower middle income countries: list according to WHO criteria (see website)

*** Copy of student ID required

Please be advised that only credit card payments will be accepted for all on-site payments.

Cash payments will not be accepted!

The registration fee includes:

- Access to the scientific sessions incl. Meet the Professor
- Access to the exhibition
- Abstract E-book
- Certificate of attendance
- Welcome reception and opening ceremony
- Access to Proceedings
- Access to video podcasts of the Clinical Practice Sessions

Bring a Friend Competition

1. Top Prize (1 winner): Bring 10 or more friends/colleagues to the meeting and your name will automatically be included in a raffle for free registration, 2 congress dinner tickets, and 3 hotel nights for the next IAPRD Congress.
2. Second Prize (2 winners): Bring 5 or more friends and your name will automatically be included in a raffle for free registration and 2 hotel nights for the next IAPRD Congress.
3. Third Prize (5 winners): Bring 3 or more friends and your name will automatically be included in a raffle for free registration to the next IAPRD Congress.

When registering, your friends/colleagues will need to include your name in the “What has drawn your attention to this Congress” box so that you can get credit!

All winners will be notified by e-mail after the Congress.

CERTIFICATION

CME Accreditation

The XXII World Congress on Parkinson’s Disease and Related Disorders, Ho Chi Minh City, Vietnam, 12/11/2017-15/11/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 20 European CME credits (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on converting EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Certificate of Attendance

To obtain the CME accreditation, please complete the Evaluation Form that will be sent to you via email after the conference. The CME certificate will be sent to you after the completion of the form.

TRAVEL GRANTS

This year's Congress Travel Awards are sponsored by both the International Association of Parkinsonism and Related Disorders and the Melvin Yahr International Parkinson's Disease Foundation. The awards are aimed at promoting participation in the Congress by young researchers worldwide, under the age of 35.

Two levels of travel grants:

1. Awards for young participants from high-income countries: up to 250 USD & registration fees.
2. Awards for young participants from low-income to medium-income countries: up to 750 USD & registration fees.

Regulations:

1. Applicants have to be under the age of 35 at the opening date of the Congress.
2. All applicants must submit an abstract (with applicant as first author) to be reviewed by the Abstract Committee.
3. The grant application has to refer to the submitted abstract, which must be approved by the Abstract Committee.
4. The applicant may send more than one abstract, and at least one of them must be approved by the Abstract Committee.
5. Indication of intent to apply for a grant must be given when submitting the abstract.
6. At the same time, all applicants must also submit
 - a recent high-resolution passport photo
 - a copy of their passport
 - a CV with an undersigned recommendation from the head of your department.

Information for Travel Award Winners 2017:

The Travel Grant is to be considered as a financial support for travel costs and cannot be paid out in cash or wired in advance of the congress. The above mentioned amount will only be wired upon presentation of travel receipts (invoices for flights, hotel accommodation incl. breakfast, boarding passes, train tickets, taxi, visa fee) and returned travel reimbursement form.

All Travel Grant requests have to be sent to Interplan by 30 November 2017.

A delayed submission of travel costs cannot be considered.

The Congress financial rules do not allow reimbursement of additional expenses (e.g. social congress program, tours, accompanying persons, business or first class travel, meals, internet access etc.).

SOCIAL PROGRAM

Sunday, 12 November 2017

WELCOME RECEPTION – GET-TOGETHER

The Welcome Reception on Sunday evening is the place to connect with other experts, physicians and researchers from around the globe.

Please join us in this informal get-together to greet old friends, meet new colleagues, and exchange impressions of the Congress. Enjoy traditional Vietnamese finger food in the casual atmosphere of the Gem Center.

All industrial exhibitors, delegates and speakers are welcome to attend. The fee for the Welcome Reception is included in the Congress registration.

The Welcome Reception will take place on Sunday, 12 November 2017 at 19:30 pm, directly after the Opening Ceremony at the GEM Center within the Exhibition Area.

Address: 08 Nguyen Binh Khiem Street, Da Kao Ward,
District 1, Ho Chi Minh City, Vietnam

Ticket: Included in Registration Fee

SOCIAL PROGRAM

Monday, 13 November 2017

CONGRESS DINNER – COLORS OF VIETNAM

Please join us for the Congress dinner on Monday, 13 November 2017 at 19:00 pm in the best of downtown Saigon, at the Rex Hotel.

With its heritage dating back to the early 20th century, the Rex Hotel offers the perfect setting to enjoy an evening with traditional Vietnamese cuisine and a cultural program. The Rex Hotel has witnessed ups and down over the city's history and has been rebuilt to become one of its most treasured monuments.

We look forward to welcoming you at the Rex Hotel for an atmospheric evening with your colleagues and friends.

Address: 141 Nguyen Hue, Ben Nghe, Quan 1, Ho Chi Minh, Vietnam

Ticket: € 85,00 per person incl. food & selection of beverages for 3 hours



HO CHI MINH CITY

Ho Chi Minh City, formerly Saigon, is the business and financial hub of Vietnam, with a prominent history dating back hundreds of years.

The Khmers originally settled the region, with the Vietnamese taking over in the 17th century. The French conquered Saigon, as it was then known, in 1859, and made it the capital of Cochin China in 1862, which resulted in elegant architecture and broad boulevards that are still present to this day.

At the peak of the Vietnam War in 1969, the city had 4.5 million inhabitants who were all evacuated when Saigon and the rest of the South fell to North Vietnam in 1975.

Today, Ho Chi Minh City is a popular tourist destination due to its rich culture, classic French architecture, and sleek skyscrapers, as well as ornate temples and pagodas.



CONGRESS VENUE – GEM CENTER

GEM CENTER

08 Nguyen Binh Khiem Street, Da Kao Ward,
District 1
Ho Chi Minh City, Vietnam
Tel.: 0084 83 91 17 070
Fax.: 0084 83 91 17 575

www.gemcenter.com.vn



The GEM Center is considered the premier venue for events in the Central Business District of Ho Chi Minh City. This state of the art facility is equipped with the latest technology and is conveniently located in the city center, in the area known as Northern District 1. This district is the commercial center of Ho Chi Minh, where the main political, financial, and cultural life of the city takes place.



HOW TO GET THERE

From the Airport:

Airport Tan-Son-Nhat is about 8 km and approximately 26 minutes by car from the GEM Center. Taxis are always available and stand-by at the airport. The approximate costs from the airport to the GEM Center (or city center) are \$10.00 one way.

From the Main Railway Station:

The Ho Chi Minh Railway station (main station) is about 5 km and approximately 15 minutes by car away from the GEM Center and at the same time the closest one. A taxi costs about \$ 8.00.

From the City Center:

We suggest to take a taxi from the city center to the GEM Center.

Taxi Telephone Numbers:

VINASUN +84 (0)28 38 272727

MAI LINH +84 (0)28 38 383838

The GEM Center is located between the main streets Dien Bien Phu and Nguyen Thi Minh Khai, which connects District 1 with District 3.

If you follow either one of these two main roads and turn into Nguyen Binh Khiem Street, you will reach and easily recognize the Congress Center by its extraordinary facade, which is adorned with planted trees interspersed along the vertical expanse of the building.

Vietnam has a comprehensive public transport system. Planes, trains and buses cover the entire country.

Contact VexploreTours for more information about airport shuttles and bus transfers:
res.iaprd2017@vexploretours.com

GOOD TO KNOW

BANKS

Banks are open from 7:30 / 8:00 am to 16:30 pm. Some banks are open on Saturday morning from 8:00 until 11:30 am. Sundays closed.

CLOAKROOM

There is a no supervised cloakroom available at the GEM Congress Center, but a luggage storage will be provided free of charge.

CURRENCY

The Vietnamese currency is the Dong. US dollars, preferably new & clean bills, are accepted almost everywhere. We recommend exchanging only a small amount at a time since Vietnamese bank notes are issued only in small denominations. American-issued VISA, Mastercard and American Express cards are accepted in major hotels, restaurants, and shops in the urban areas. While traveler's checks are also accepted, exchanging them for Dong can be quite inconvenient. ATM machines are available in Ho Chi Minh City and other major cities. For registration fees and tickets for social programs, only credit card payments accepted.

DISCLAIMER & PERSONAL INSURANCE

The organizers cannot be held responsible for any personal injury, loss, damage or accident to private property, or for additional expenses incurred as a result of delays or changes in air, road or other services, strikes, sickness, weather and other causes. All participants are encouraged to make their own arrangements for health and travel insurance.

ELECTRICITY

Vietnam operates on a 220V supply voltage and 50Hz. There are several plug types in Vietnam, but the predominant is the European plug (pin round socket). In some parts of Vietnam, such as Ho Chi Minh City, you may also find the flat jacks.

FOOD & DRINKS

A light lunch, coffee, tea and water will be offered during break times in the exhibition area and are included in the registration fee.

INTERNET

The GEM Congress Center provides WiFi in public areas free of charge with no warranty.

LANGUAGE

The official language of the Congress is English.

PROGRAM CHANGES

The Organizers cannot assume liability for any changes in the program due to external unforeseen circumstances.

TRANSPORTATION

Your travel within Ho Chi Minh City is not included in your Congress ticket. In order to arrange an individual or group transfer please contact res.iaprd2017@vexploretravels.com.

SAFETY

Vietnam is a safe country to travel in. Petty theft is a problem in tourist centers, where snatch and grab robberies are a major issue. Violent crime against foreigners remains rare.

SMOKING POLICY

Smoking is not allowed at the venue; the meeting is a non-smoking event.

TIMEZONE

Reunified Vietnam follows UTC+7, which is 7 hours ahead of Greenwich Mean Time and Coordinated Universal Time.

TELEPHONE

The international access code of Ho Chi Minh City is +84 (+84 8) having 8-digit subscriber numbers. Local emergency telephone numbers are

Police: 113 Fire: 114 Ambulance – First Aid: 115

VISA

Most visitors to Vietnam need a visa to enter the country.

Visa on Arrival Application Process:

1. Requesting an authorized letter from Vietnam Immigration Dept., (fee required).

Documents needed:

- Copy of passport
 - Arrival/departure date with flight details (planned)
 - The first and the last entry city of Vietnam (Ho Chi Minh City or Hanoi)
 - The place you will get the visa (upon-arrival at the airport in Vietnam or at the Vietnam Embassy)
2. The authorized letter needs to be handed in at the visa issuing offices on arrival at International Airport of Vietnam.
 3. Proceeding at the airport
When arriving at the airport, you need to go to the LANDING VISA COUNTER. You will fill out the visa application form and present your valid passport, 2 passport (4x6) photos and the visa authorized letter confirmation. A visa fee applies. Your visa will then be issued within 30 minutes.

For more information, please visit the website: www.lanhsuvietnam.gov.vn/

Your passport must be at least valid more than 6 months after your arrival date in Vietnam.



IAPRD ASSOCIATION

ABOUT THE IAPRD

THE INTERNATIONAL ASSOCIATION OF PARKINSONISM AND RELATED DISORDERS

Over fifty years ago, the International Association of Parkinsonism and Related Disorders was established by the World Federation of Neurology to promote and monitor research developments, as well as to foster communication among neuroscientists in this field. Today, this IAPRD is an international, professional association of clinicians, scientists and other healthcare professionals who are interested in neurodegenerative disorders like Parkinson's disease, secondary parkinsonisms, hyperkinetic and hypokinetic movement disorders, and more generally any disorder affecting muscle tone and motor control. The most common clinical disorders and/or symptoms of interest to us are:

- Genetic and idiopathic Parkinson's disease and other parkinsonism
- Genetic and idiopathic disorders with dystonia
- Huntington's disease and other disorders with chorea
- Cerebellar disorders
- Tremor, myoclonus, tics, ballism
- Huntington's disease, chorea and Gilles de la Tourette's syndrome, psychogenic and psychiatric movement disorders
- Movement disorder-related non-motor disorders, such as disorders of the autonomic nervous system, mood disorders, sleep disorders (including excess daytime sleepiness, REM sleep behaviour disorders, restless legs syndrome, and periodic limb movements), psychiatric disorders (including impulse control disorders, executive dysfunction, dementia, delusions and hallucinations).

The association has Full Members, Associate Members, and Honorary Members.

ASSOCIATE MEMBER SIGN UP FORM

For an online version of the membership sign up form please go to www.iaprd.org/membership.html . After submitting this form you'll be redirected to PayPal in order to pay the sum of €70,- for a biannual subscription to the PRD journal.

IAPRD ASSOCIATE MEMBER FORM

Prof

Dr

Mr

Ms

*First Name

*Family Name

*Your E-Mail Address

*Address

*Postal Code

*City

*Country

State (optional)

Company / University / Other (optional)

Phone Number (optional)

* I have read and agree with the Terms and Conditions
(see www.iaprd.org/membership.html)

Signature

To be admitted as an Associate Member, please fill in the application form with your personal data, and declare that you endorse the objectives and mission of the International Association of Parkinson and Related Disorders, as described in the bylaws and mission statement. Applicants will receive associate membership automatically, although the Board retains the right to refusal of admission.

The Associate Membership will be free of charge, but an administrative fee of € 70,00 for two years will be charged, which also includes the IAPRD journal. The fee will be waived for the first two years after participating in one of our World Congresses.

Please return the form to: franswolters@hotmail.com

IAPRD COMMITTEES

SCIENTIFIC PROGRAM EXECUTIVE COMMITTEE

Hubert Fernandez (United States), Chair
Angelo Antonini (Italy)
Ted Dawson (United States)
Kazuko Hasegawa (Japan)
Daniel Truong (United States)
Erik Ch. Wolters (The Netherlands)

SCIENTIFIC PROGRAM COMMITTEE

Elena Moro (France), Chair
Fabrizio Stocchi (Italy), Co-Chair
Jean-Philippe Azulay (France)
Roongroj Bhidayasiri (Thailand)
Rupam Borgohain (India)
Shendi Chen (China)
Carlo Colosimo (Italy)
Cindy Comella (United States)
Alberto J. Espay (United States)
Alfonso Fasano (Italy)
Etienne Hirsch (France)
Takeshi Ikeuchi (Japan)
Ioannis Isaias (Germany)
Beomseok Jeon (Republic of Korea)
Prakash Kumar (Singapore)
Mark F. Lew (United States)

Elan D. Louis (United States)
Rukmini Mridula (India)
Thomas Müller (Germany)
Rajesh Pahwa (United States)
Pramod Pal (India)
Andreas Puschmann (Sweden)
Maja Relja (Croatia)
Owen A. Ross (United States)
Jan Roth (Czech Republic)
Huifang Shang (China)
David K. Simon (United States)
Carlos Singer (United States)
Michele Tagliati (United States)
Diego Torres-Russotto (United States)
Francesc Valldeoriola (Spain)
Yih-Ru Wu (Taiwan)

CONGRESS GENERAL COMMITTEE

Alberto Albanese (Italy)
Alim Louis Benabid (France)
Kalyanbrata Bhattacharyya (India)
David J. Brooks (United Kingdom)
K Ray Chaudhuri (United Kingdom)
Kelvin L. Chou (United States)
Sun Ju Chung (Korea)
Dirk Dressler (Germany)
Karen Frei (United States)
Stuart Isaacson (United States)

Saltanat Kamenova (Kazakhstan)
Joachim Kurt Krauss (Germany)
Ailton Melo (Brazil)
Gianni Pezzoli (Italy)
Gulnora Rakhimbaeva (Uzbekistan)
Tanya Simuni (United States)
Maria Stamelou (Greece)
Gregor Wenning (Austria)

CONGRESS PROCEEDINGS COMMITTEE

Zbigniew K. Wszolek (United States)
Vincenzo Bonifati (The Netherlands)
Susan Calne (Canada)
Jonathan Carr (South Africa)
Minh Le (Vietnam)

Ronald Pfeiffer (United States)
Robert Rodnitzky (United States)
Eng-King Tan (Singapore)
Daniel Truong (United States)

ABSTRACT REVIEW COMMITTEE

Chin-Hsien Lin (Taiwan)
Sarah Pirio Richardson (United States)
Young H. Sohn (Republic of Korea)
Elena Moro (France)
Dirk Dressler (Germany)
Yih-Ru Wu (Taiwan)

Irena Rektorova (Czech Republic)
Eng-King Tan (Singapore)
Christian Baumann (Germany)
Genko Oyama (Japan)

LOCAL ORGANIZING COMMITTEE

Tran Diep Tuan (Vietnam)
Nguyễn Hoàng Bắc (Vietnam)
Le Duc Hinh (Vietnam)
Nguyen Thi Hung (Vietnam)
Nguyen Trong Hung (Vietnam)

Le Minh (Vietnam)
Tran Ngoc Tai (Vietnam)
Vo Nguyen Ngoc Trang (Vietnam)
Le Van Tuan (Vietnam)

INDUSTRY LIAISON COMMITTEE

Fabrizio Stocchi (Italy)
Alberto Albanese (Italy)
Roongroj Bhidayasiri (Thailand)
Shendi Chen (China)

Dirk Dressler (Germany)
Hubert Fernandez (United States)
Elena Moro (France)
Gianni Pezzoli (Italy)

AWARD COMMITTEE

Mark Lew (United States)
Jasem Al-Hashel (Kuwait)
Hung Trong Nguyen (Vietnam)

Thien Thien Lim (Malaysia)
Diego Torres-Russotto (United States)




INDUSTRY

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support.

This section contains information that is promotional in nature, distinct from the scientific/educational elements of the main CME/CPD event.

EXHIBITION FLOOR PLAN

Grand Pollux – Level 3



Exhibition opening times

Sunday, 12 November 2017	19:00 – 20:30
Monday, 13 November 2017	09:00 – 17:00
Tuesday, 14 November 2017	09:00 – 17:30

EXHIBITORS

Exhibitor Name	Booth
AbbVie Inc.	A.08
Boston Scientific International	A.05
Elsevier B.V.	A.02
IAPRD International Association of Parkinsonism and Related Disorders	A.01
Ipsen Pharma Singapore Pte. Ltd.	A.06
Medtronic	A.04
UCB Pharma (Hong Kong) Limited & Abbott Laboratories S.A.	A.07
World Parkinson Coalition	A.03

CODE OF TRANSPARENCY

Interplan publishes the conditions and the scope of the support provided by EFPIA member companies to the IAPRD Congress on a voluntary basis. The publication will be carried out before and during the execution of the Congress.

For the industry partners mentioned above, we are herewith informing about their overall support within the framework of the IAPRD Congress 2017.

SPONSORS / SUPPORTERS

We kindly thank all our sponsors for their support!

Sponsor names are in alphabetical order.

PLATINUM SUPPORTER

Acadia Pharmaceuticals Inc.



GOLD SUPPORTERS

AbbVie Inc.



Neurocrine Biosciences, Inc.



F. Hoffmann-La Roche Ltd.



Sunovion Pharmaceuticals Inc.



Ipsen Biopharmaceuticals, Inc.



Teva Pharmaceutical Industries Limited



ADDITIONAL SUPPORTERS

Britannia Pharmaceuticals



Merz Pharmaceuticals GmbH



evidentia.med gmbh

evidentia.med

US WorldMeds



This event is supported, in part, by funding from industry. All support will be managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support.

CORPORATE SESSIONS

Sunday, 12 November 2017

10:00 – 13:00



Pre-Congress Corporate Session “A Deeper Dive into the Recognition, Impact and Treatment of Parkinson Psychosis”

This session is supported by ACADIA Pharmaceuticals Inc.

**Room
Castor 1**

Chair: J. Friedman, Rhode Island, United States

Learning Objectives

- Understand how Parkinson psychosis develops in the course of the disease
- Recognize how the clinical presentation and challenges of patients experiencing Parkinson Disease psychosis
- Know the treatment options for this condition and when to intervene

10:00 – 10:40

How Common is PD Psychosis and How is it Recognized?

J. Friedman, Rhode Island, United States

10:40 – 10:50

Discussion

10:50 – 11:30

Update on our Current Understanding of the Pathogenesis of PD Psychosis

A. P. Strafella, Toronto, Canada

11:30 – 11:40

Discussion

11:40 – 12:20

How, What and When to Treat PD Psychosis

K. Frei, Loma Linda, United States

12:20 – 12:30

Discussion

Monday, 13 November 2017

12:00 – 13:30



“Off States in Parkinson Disease: Options Beyond Oral Medications”

This session is sponsored by Sunovion Pharmaceuticals.

**Room
Castor 3**

Chair: H. Fernandez, Cleveland, United States

12:00 – 12:25

Understanding and Appreciating the OFF Spectrum in Parkinson Disease

H. Fernandez, Cleveland, United States


12:25 – 12:50

Pathophysiological Mechanisms of OFF States in Parkinson Disease


A. Espay, Cincinnati, United States

- 12:50 – 13:15 Treatment Options and Approaches for OFF States in Parkinson Disease
T. Simuni, Chicago, United States
- 13:15 – 13:30 Panel Discussion
H. Fernandez; A. Espay; T. Simuni

Tuesday, 14 November 2017

12:00 – 13:30  **Seeing the Signs: Case Scenarios in Advanced Parkinson's Disease** **Room
Castor 3**
This session is sponsored by AbbVie.

Program will follow.

12:00 – 13:30  **"Focusing on Tardive Dyskinesia – Current Challenges and Opportunities"** **Room
Castor 1**
This session is supported by Neurocrine Biosciences, Inc.

Chair: O. Bajenaru, Bucharest, Romania

Learning Objectives

- To understand the history, symptoms, and signs of tardive dyskinesia
- To learn the epidemiology, clinical course, and impact of tardive dyskinesia on patients' lives
- To describe VMAT inhibitors in the treatment of tardive dyskinesia, including similarities and differences among available medications

- 12:00 – 12:30 The Many Faces of Tardive Dyskinesia: History and Phenomenology
W. Ondo, Houston, United States
- 12:30 – 13:00 The Prevalence, Clinical Course and Impact of Tardive Dyskinesia
G. A. Maguire, Riverside, United States
- 13:00 – 13:30 Are all VMAT2 Inhibitors the Same in the Treatment of Tardive Dyskinesia?
C. Comella, Chicago, United States

DATA PROTECTION

DATA PROTECTION

INTERPLAN AG handles all personal data according to the laws of § 4 under the Federal Data Protection Act.

For your registration to a congress organized by Interplan, the collecting, saving and processing of your personal data is imperative. This is done solely as a means of the organization and completion of the event.

The collected data will only be passed onto a third party, who is directly involved with the running of the congress and when the organizational procedure makes this necessary (operator, hotel, visa, social program etc.).

The legislator requires us to obtain the participant's consent. The registration to a congress organized by us is not possible if we do not get this.

When registering you declare the following: I hereby declare my consent that all the information made by me to my person within the handling of the above mentioned congress is filed, saved, processed and the demands made above can correspondingly be passed onto a third party.

I agree to receive information on future congresses related to the subject of this event. Declaration of consent can be retracted at any time by sending a message to Interplan AG, Landsberger Strasse 155, 80687 München, iaprd@interplan.de

IMPRINT

SCIENTIFIC ORGANIZER

IAPRD

The International Association of Parkinsonism and Related Disorders

Van Eeghenstraat 83, 1071 EX Amsterdam, The Netherlands

E-mail: info@iaprd.org

Website: www.iaprd.org



CONGRESS ORGANIZATION

INTERPLAN

Congress, Meeting & Event Management AG

Office Hamburg

Kaiser-Wilhelm-Strasse 93, 20355 Hamburg, Germany

Phone: +49 40 325092-37 / Fax: +49 40 325092-44

E-mail: IAPRD@interplan.de

Website: www.interplan.de



LOCAL PARTNER FOR SOCIAL PROGRAM, HOTEL RESERVATIONS AND TOURS

Vexplore Tours

500. North State College Blvd., Suite 1100

Orange, CA 92868, USA

E-mail: res.iaprd2017@vexploretours.com

Website: www.vexploretours.com



IMAGE SOURCES

Photos provided by

©Vexplore tours

©Rexhotel

©iStock.com

©GEM Center

Scientific Program subject to change, status October 2017

SAVE THE DATE



LYON / FRANCE

WORLD CONGRESS ON PARKINSON'S
DISEASE AND RELATED DISORDERS

2018

19 – 22 August



www.iaprd-world-congress.com